JP2008535790A - サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体 - Google Patents

Info

Publication number

JP2008535790A

JP2008535790A JP2007558290A JP2007558290A JP2008535790A JP 2008535790 A JP2008535790 A JP 2008535790A JP 2007558290 A JP2007558290 A JP 2007558290A JP 2007558290 A JP2007558290 A JP 2007558290A JP 2008535790 A JP2008535790 A JP 2008535790A

Authority

JP

Japan

Prior art keywords

subject

disease

treating

ring

preventing

Prior art date

2005-03-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102000011990 Sirtuin Human genes 0.000 title claims description 182
• 108050002485 Sirtuin Proteins 0.000 title claims description 182
• 150000005414 N-phenylbenzamides Chemical class 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 331
• 238000000034 method Methods 0.000 claims abstract description 194
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 177
• 201000010099 disease Diseases 0.000 claims abstract description 129
• 239000003814 drug Substances 0.000 claims abstract description 53
• 208000035475 disorder Diseases 0.000 claims abstract description 47
• 230000001965 increasing effect Effects 0.000 claims abstract description 43
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
• 201000011510 cancer Diseases 0.000 claims abstract description 28
• 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 28
• 239000000203 mixture Substances 0.000 claims abstract description 28
• 230000004770 neurodegeneration Effects 0.000 claims abstract description 25
• 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 20
• 230000032683 aging Effects 0.000 claims abstract description 19
• 230000035882 stress Effects 0.000 claims abstract description 18
• 208000015294 blood coagulation disease Diseases 0.000 claims abstract description 11
• 230000002438 mitochondrial effect Effects 0.000 claims abstract description 11
• 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 10
• 230000008901 benefit Effects 0.000 claims abstract description 10
• -1 oxazolopyridyl Chemical group 0.000 claims description 150
• 230000000694 effects Effects 0.000 claims description 131
• 210000004027 cell Anatomy 0.000 claims description 102
• 150000003839 salts Chemical class 0.000 claims description 69
• 108090000623 proteins and genes Proteins 0.000 claims description 54
• 125000000217 alkyl group Chemical group 0.000 claims description 49
• 125000003118 aryl group Chemical group 0.000 claims description 46
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 45
• 208000024891 symptom Diseases 0.000 claims description 40
• 102000004169 proteins and genes Human genes 0.000 claims description 38
• 229940079593 drug Drugs 0.000 claims description 37
• 230000006378 damage Effects 0.000 claims description 33
• 239000003112 inhibitor Substances 0.000 claims description 33
• 102000000478 Sirtuin 3 Human genes 0.000 claims description 32
• 210000003169 central nervous system Anatomy 0.000 claims description 32
• 201000001119 neuropathy Diseases 0.000 claims description 32
• 239000002246 antineoplastic agent Substances 0.000 claims description 31
• 230000007823 neuropathy Effects 0.000 claims description 31
• 102000000344 Sirtuin 1 Human genes 0.000 claims description 30
• 108010041191 Sirtuin 1 Proteins 0.000 claims description 30
• 108091005770 SIRT3 Proteins 0.000 claims description 27
• 125000003367 polycyclic group Chemical group 0.000 claims description 27
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 26
• 210000003205 muscle Anatomy 0.000 claims description 25
• 125000001424 substituent group Chemical group 0.000 claims description 25
• 229940002612 prodrug Drugs 0.000 claims description 23
• 239000000651 prodrug Substances 0.000 claims description 23
• 208000006011 Stroke Diseases 0.000 claims description 22
• 230000000302 ischemic effect Effects 0.000 claims description 22
• 230000004584 weight gain Effects 0.000 claims description 22
• 235000019786 weight gain Nutrition 0.000 claims description 22
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 20
• 206010022489 Insulin Resistance Diseases 0.000 claims description 18
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
• 230000003213 activating effect Effects 0.000 claims description 18
• 229940127089 cytotoxic agent Drugs 0.000 claims description 18
• 230000007423 decrease Effects 0.000 claims description 18
• 125000000623 heterocyclic group Chemical group 0.000 claims description 17
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 17
• 208000007536 Thrombosis Diseases 0.000 claims description 16
• 108010040003 polyglutamine Proteins 0.000 claims description 16
• 229920000155 polyglutamine Polymers 0.000 claims description 16
• 230000030833 cell death Effects 0.000 claims description 15
• 125000005843 halogen group Chemical group 0.000 claims description 15
• 201000006417 multiple sclerosis Diseases 0.000 claims description 14
• 102000004877 Insulin Human genes 0.000 claims description 13
• 108090001061 Insulin Proteins 0.000 claims description 13
• 208000012902 Nervous system disease Diseases 0.000 claims description 13
• 229940125396 insulin Drugs 0.000 claims description 13
• 230000001225 therapeutic effect Effects 0.000 claims description 13
• 208000024827 Alzheimer disease Diseases 0.000 claims description 12
• 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims description 12
• 239000003795 chemical substances by application Substances 0.000 claims description 12
• 101000863566 Homo sapiens NAD-dependent protein deacetylase sirtuin-3, mitochondrial Proteins 0.000 claims description 11
• 208000023105 Huntington disease Diseases 0.000 claims description 11
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
• 229940044683 chemotherapy drug Drugs 0.000 claims description 11
• 125000001072 heteroaryl group Chemical group 0.000 claims description 11
• 102000056482 human SIRT1 Human genes 0.000 claims description 11
• 208000028867 ischemia Diseases 0.000 claims description 11
• 230000035945 sensitivity Effects 0.000 claims description 11
• 238000001356 surgical procedure Methods 0.000 claims description 11
• 208000018737 Parkinson disease Diseases 0.000 claims description 10
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
• 229910052736 halogen Inorganic materials 0.000 claims description 9
• 150000002367 halogens Chemical class 0.000 claims description 9
• 208000010125 myocardial infarction Diseases 0.000 claims description 9
• 230000001737 promoting effect Effects 0.000 claims description 9
• 230000004936 stimulating effect Effects 0.000 claims description 9
• 230000004083 survival effect Effects 0.000 claims description 9
• 206010020772 Hypertension Diseases 0.000 claims description 8
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 8
• 230000017531 blood circulation Effects 0.000 claims description 8
• 230000006196 deacetylation Effects 0.000 claims description 8
• 238000003381 deacetylation reaction Methods 0.000 claims description 8
• 230000005764 inhibitory process Effects 0.000 claims description 8
• 210000000229 preadipocyte Anatomy 0.000 claims description 8
• 230000004393 visual impairment Effects 0.000 claims description 8
• 230000015572 biosynthetic process Effects 0.000 claims description 7
• 230000004069 differentiation Effects 0.000 claims description 7
• 230000000451 tissue damage Effects 0.000 claims description 7
• 231100000827 tissue damage Toxicity 0.000 claims description 7
• 206010019280 Heart failures Diseases 0.000 claims description 6
• 206010021143 Hypoxia Diseases 0.000 claims description 6
• 125000003545 alkoxy group Chemical group 0.000 claims description 6
• 125000005842 heteroatom Chemical group 0.000 claims description 6
• 230000007954 hypoxia Effects 0.000 claims description 6
• 229910052757 nitrogen Inorganic materials 0.000 claims description 6
• 229910052760 oxygen Inorganic materials 0.000 claims description 6
• 208000011580 syndromic disease Diseases 0.000 claims description 6
• 206010003694 Atrophy Diseases 0.000 claims description 5
• 206010010904 Convulsion Diseases 0.000 claims description 5
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
• 229940122803 Vinca alkaloid Drugs 0.000 claims description 5
• 206010047571 Visual impairment Diseases 0.000 claims description 5
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
• 239000003146 anticoagulant agent Substances 0.000 claims description 5
• 230000037444 atrophy Effects 0.000 claims description 5
• 230000032677 cell aging Effects 0.000 claims description 5
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
• 229960004316 cisplatin Drugs 0.000 claims description 5
• 102000045076 human SIRT3 Human genes 0.000 claims description 5
• 229960003966 nicotinamide Drugs 0.000 claims description 5
• 235000005152 nicotinamide Nutrition 0.000 claims description 5
• 239000011570 nicotinamide Substances 0.000 claims description 5
• 238000011084 recovery Methods 0.000 claims description 5
• 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims description 5
• 208000029257 vision disease Diseases 0.000 claims description 5
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
• 206010002383 Angina Pectoris Diseases 0.000 claims description 4
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
• 208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
• 230000037396 body weight Effects 0.000 claims description 4
• 208000029078 coronary artery disease Diseases 0.000 claims description 4
• 210000004351 coronary vessel Anatomy 0.000 claims description 4
• 230000007812 deficiency Effects 0.000 claims description 4
• 230000001771 impaired effect Effects 0.000 claims description 4
• 210000004962 mammalian cell Anatomy 0.000 claims description 4
• 125000002560 nitrile group Chemical group 0.000 claims description 4
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 230000035935 pregnancy Effects 0.000 claims description 4
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
• 229910052717 sulfur Inorganic materials 0.000 claims description 4
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
• 230000005778 DNA damage Effects 0.000 claims description 3
• 231100000277 DNA damage Toxicity 0.000 claims description 3
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
• 206010047249 Venous thrombosis Diseases 0.000 claims description 3
• 125000004423 acyloxy group Chemical group 0.000 claims description 3
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
• 206010003246 arthritis Diseases 0.000 claims description 3
• 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 3
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
• 125000002619 bicyclic group Chemical group 0.000 claims description 3
• 230000033228 biological regulation Effects 0.000 claims description 3
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 230000020764 fibrinolysis Effects 0.000 claims description 3
• 125000001041 indolyl group Chemical group 0.000 claims description 3
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 3
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
• 210000001328 optic nerve Anatomy 0.000 claims description 3
• 125000004193 piperazinyl group Chemical group 0.000 claims description 3
• 125000003386 piperidinyl group Chemical group 0.000 claims description 3
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
• 229960004618 prednisone Drugs 0.000 claims description 3
• 208000007056 sickle cell anemia Diseases 0.000 claims description 3
• 230000004580 weight loss Effects 0.000 claims description 3
• 206010000234 Abortion spontaneous Diseases 0.000 claims description 2
• 206010056867 Activated protein C resistance Diseases 0.000 claims description 2
• 206010003658 Atrial Fibrillation Diseases 0.000 claims description 2
• 206010008748 Chorea Diseases 0.000 claims description 2
• 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
• 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
• 208000005189 Embolism Diseases 0.000 claims description 2
• 206010014561 Emphysema Diseases 0.000 claims description 2
• 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
• 208000010412 Glaucoma Diseases 0.000 claims description 2
• 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 2
• 206010020365 Homocystinuria Diseases 0.000 claims description 2
• 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
• 206010027476 Metastases Diseases 0.000 claims description 2
• 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
• 208000003435 Optic Neuritis Diseases 0.000 claims description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 2
• 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
• 201000005660 Protein C Deficiency Diseases 0.000 claims description 2
• 206010051292 Protein S Deficiency Diseases 0.000 claims description 2
• 206010038563 Reocclusion Diseases 0.000 claims description 2
• 206010049771 Shock haemorrhagic Diseases 0.000 claims description 2
• 208000001435 Thromboembolism Diseases 0.000 claims description 2
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 2
• 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
• 229930003427 Vitamin E Natural products 0.000 claims description 2
• 238000002399 angioplasty Methods 0.000 claims description 2
• 230000002921 anti-spasmodic effect Effects 0.000 claims description 2
• 206010003119 arrhythmia Diseases 0.000 claims description 2
• 230000006793 arrhythmia Effects 0.000 claims description 2
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 2
• 208000012601 choreatic disease Diseases 0.000 claims description 2
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
• 230000009089 cytolysis Effects 0.000 claims description 2
• 230000010339 dilation Effects 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
• 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims description 2
• 208000027866 inflammatory disease Diseases 0.000 claims description 2
• 201000010901 lateral sclerosis Diseases 0.000 claims description 2
• 208000002780 macular degeneration Diseases 0.000 claims description 2
• 230000009401 metastasis Effects 0.000 claims description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
• 208000015994 miscarriage Diseases 0.000 claims description 2
• 125000002757 morpholinyl group Chemical group 0.000 claims description 2
• 208000005264 motor neuron disease Diseases 0.000 claims description 2
• 201000006938 muscular dystrophy Diseases 0.000 claims description 2
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
• 201000008383 nephritis Diseases 0.000 claims description 2
• 235000021049 nutrient content Nutrition 0.000 claims description 2
• 235000015097 nutrients Nutrition 0.000 claims description 2
• 230000008723 osmotic stress Effects 0.000 claims description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 2
• 239000002510 pyrogen Substances 0.000 claims description 2
• 230000035939 shock Effects 0.000 claims description 2
• 208000000995 spontaneous abortion Diseases 0.000 claims description 2
• 206010043554 thrombocytopenia Diseases 0.000 claims description 2
• 229940088594 vitamin Drugs 0.000 claims description 2
• 229930003231 vitamin Natural products 0.000 claims description 2
• 235000013343 vitamin Nutrition 0.000 claims description 2
• 239000011782 vitamin Substances 0.000 claims description 2
• 235000019165 vitamin E Nutrition 0.000 claims description 2
• 229940046009 vitamin E Drugs 0.000 claims description 2
• 239000011709 vitamin E Substances 0.000 claims description 2
• 210000003527 eukaryotic cell Anatomy 0.000 claims 10
• 239000000825 pharmaceutical preparation Substances 0.000 claims 4
• 229940127557 pharmaceutical product Drugs 0.000 claims 4
• 230000000973 chemotherapeutic effect Effects 0.000 claims 3
• 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 claims 2
• 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 claims 2
• 208000022873 Ocular disease Diseases 0.000 claims 2
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
• PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 1
• 102000007370 Ataxin2 Human genes 0.000 claims 1
• 108010032951 Ataxin2 Proteins 0.000 claims 1
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
• AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
• 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 claims 1
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 1
• 208000027747 Kennedy disease Diseases 0.000 claims 1
• 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
• 208000021642 Muscular disease Diseases 0.000 claims 1
• 201000009623 Myopathy Diseases 0.000 claims 1
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
• 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
• 206010057430 Retinal injury Diseases 0.000 claims 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
• 201000003622 Spinocerebellar ataxia type 2 Diseases 0.000 claims 1
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
• 201000003620 Spinocerebellar ataxia type 6 Diseases 0.000 claims 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
• 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
• 230000002785 anti-thrombosis Effects 0.000 claims 1
• 239000003963 antioxidant agent Substances 0.000 claims 1
• 235000006708 antioxidants Nutrition 0.000 claims 1
• 230000000386 athletic effect Effects 0.000 claims 1
• 235000019577 caloric intake Nutrition 0.000 claims 1
• 230000004637 cellular stress Effects 0.000 claims 1
• 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
• 230000002708 enhancing effect Effects 0.000 claims 1
• 210000003743 erythrocyte Anatomy 0.000 claims 1
• 208000027826 familial dysfibrinogenemia Diseases 0.000 claims 1
• 229940014144 folate Drugs 0.000 claims 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
• 235000019152 folic acid Nutrition 0.000 claims 1
• 239000011724 folic acid Substances 0.000 claims 1
• 230000004410 intraocular pressure Effects 0.000 claims 1
• AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
• 235000019136 lipoic acid Nutrition 0.000 claims 1
• 206010028417 myasthenia gravis Diseases 0.000 claims 1
• 208000004296 neuralgia Diseases 0.000 claims 1
• 208000018360 neuromuscular disease Diseases 0.000 claims 1
• 208000021722 neuropathic pain Diseases 0.000 claims 1
• 230000001898 pallidal effect Effects 0.000 claims 1
• 210000000463 red nucleus Anatomy 0.000 claims 1
• 210000001525 retina Anatomy 0.000 claims 1
• 229960002477 riboflavin Drugs 0.000 claims 1
• 235000019192 riboflavin Nutrition 0.000 claims 1
• 239000002151 riboflavin Substances 0.000 claims 1
• 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
• 208000001076 sarcopenia Diseases 0.000 claims 1
• 229910052711 selenium Inorganic materials 0.000 claims 1
• 239000011669 selenium Substances 0.000 claims 1
• 235000011649 selenium Nutrition 0.000 claims 1
• 229940091258 selenium supplement Drugs 0.000 claims 1
• 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 claims 1
• 201000003632 spinocerebellar ataxia type 7 Diseases 0.000 claims 1
• 230000008961 swelling Effects 0.000 claims 1
• 229960003495 thiamine Drugs 0.000 claims 1
• 235000019157 thiamine Nutrition 0.000 claims 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
• 239000011721 thiamine Substances 0.000 claims 1
• 229960002663 thioctic acid Drugs 0.000 claims 1
• 208000008589 Obesity Diseases 0.000 abstract description 16
• 235000020824 obesity Nutrition 0.000 abstract description 16
• 206010061218 Inflammation Diseases 0.000 abstract description 13
• 230000004054 inflammatory process Effects 0.000 abstract description 13
• 229940124597 therapeutic agent Drugs 0.000 abstract description 11
• 208000037765 diseases and disorders Diseases 0.000 abstract description 6
• 238000011010 flushing procedure Methods 0.000 abstract description 5
• 238000011282 treatment Methods 0.000 description 36
• 235000018102 proteins Nutrition 0.000 description 33
• 210000005036 nerve Anatomy 0.000 description 28
• 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 25
• 235000001014 amino acid Nutrition 0.000 description 25
• 150000001413 amino acids Chemical class 0.000 description 23
• 229940024606 amino acid Drugs 0.000 description 22
• 102000039446 nucleic acids Human genes 0.000 description 22
• 108020004707 nucleic acids Proteins 0.000 description 22
• 150000007523 nucleic acids Chemical class 0.000 description 22
• 241000282414 Homo sapiens Species 0.000 description 20
• 230000006870 function Effects 0.000 description 20
• 210000001519 tissue Anatomy 0.000 description 20
• 210000004556 brain Anatomy 0.000 description 19
• 208000014674 injury Diseases 0.000 description 18
• 102000003964 Histone deacetylase Human genes 0.000 description 17
• 108090000353 Histone deacetylase Proteins 0.000 description 17
• 125000003729 nucleotide group Chemical group 0.000 description 17
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 16
• 230000006907 apoptotic process Effects 0.000 description 16
• 125000003275 alpha amino acid group Chemical group 0.000 description 15
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 15
• 238000002648 combination therapy Methods 0.000 description 14
• 229950006238 nadide Drugs 0.000 description 14
• 239000002773 nucleotide Substances 0.000 description 14
• 230000001105 regulatory effect Effects 0.000 description 14
• 239000000126 substance Substances 0.000 description 14
• 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 13
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 13
• BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 13
• 235000000346 sugar Nutrition 0.000 description 13
• 208000002193 Pain Diseases 0.000 description 12
• 210000004369 blood Anatomy 0.000 description 12
• 239000008280 blood Substances 0.000 description 12
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
• 102000040430 polynucleotide Human genes 0.000 description 12
• 108091033319 polynucleotide Proteins 0.000 description 12
• 239000002157 polynucleotide Substances 0.000 description 12
• 230000002265 prevention Effects 0.000 description 12
• 241001465754 Metazoa Species 0.000 description 11
• 230000023597 hemostasis Effects 0.000 description 11
• 230000002401 inhibitory effect Effects 0.000 description 11
• 210000001428 peripheral nervous system Anatomy 0.000 description 11
• 239000002253 acid Substances 0.000 description 10
• 239000012190 activator Substances 0.000 description 10
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
• 230000014509 gene expression Effects 0.000 description 10
• 210000002569 neuron Anatomy 0.000 description 10
• 230000036407 pain Effects 0.000 description 10
• 230000008733 trauma Effects 0.000 description 10
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 10
• 229960004528 vincristine Drugs 0.000 description 10
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 10
• PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 9
• 208000032843 Hemorrhage Diseases 0.000 description 9
• 230000023555 blood coagulation Effects 0.000 description 9
• 230000001419 dependent effect Effects 0.000 description 9
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
• 239000012634 fragment Substances 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 8
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 8
• 208000030507 AIDS Diseases 0.000 description 8
• 206010036105 Polyneuropathy Diseases 0.000 description 8
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 8
• 125000001931 aliphatic group Chemical group 0.000 description 8
• 239000003416 antiarrhythmic agent Substances 0.000 description 8
• 230000000740 bleeding effect Effects 0.000 description 8
• 230000034994 death Effects 0.000 description 8
• 239000003925 fat Substances 0.000 description 8
• 235000019197 fats Nutrition 0.000 description 8
• 150000004665 fatty acids Chemical class 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 210000000578 peripheral nerve Anatomy 0.000 description 8
• 230000007824 polyneuropathy Effects 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 8
• 239000000758 substrate Substances 0.000 description 8
• 238000013518 transcription Methods 0.000 description 8
• 230000035897 transcription Effects 0.000 description 8
• 229940127291 Calcium channel antagonist Drugs 0.000 description 7
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 7
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
• 101000825628 Homo sapiens NAD-dependent protein deacetylase sirtuin-2 Proteins 0.000 description 7
• 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 7
• 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 7
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 7
• 102000000477 Sirtuin 2 Human genes 0.000 description 7
• 208000027418 Wounds and injury Diseases 0.000 description 7
• 210000003050 axon Anatomy 0.000 description 7
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
• 125000004122 cyclic group Chemical group 0.000 description 7
• 235000014113 dietary fatty acids Nutrition 0.000 description 7
• 229930195729 fatty acid Natural products 0.000 description 7
• 239000000194 fatty acid Substances 0.000 description 7
• 125000000524 functional group Chemical group 0.000 description 7
• 239000008103 glucose Substances 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 229920001184 polypeptide Polymers 0.000 description 7
• 102000004196 processed proteins & peptides Human genes 0.000 description 7
• 210000000278 spinal cord Anatomy 0.000 description 7
• IHMQOBPGHZFGLC-UHFFFAOYSA-N 5,6-dimethoxy-2,3-dihydroinden-1-one Chemical compound C1=C(OC)C(OC)=CC2=C1C(=O)CC2 IHMQOBPGHZFGLC-UHFFFAOYSA-N 0.000 description 6
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 108010092160 Dactinomycin Proteins 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 208000025966 Neurological disease Diseases 0.000 description 6
• 206010033307 Overweight Diseases 0.000 description 6
• QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 6
• LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 6
• 229960001138 acetylsalicylic acid Drugs 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 235000019789 appetite Nutrition 0.000 description 6
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 6
• 230000035602 clotting Effects 0.000 description 6
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 6
• 229960004166 diltiazem Drugs 0.000 description 6
• 229960003638 dopamine Drugs 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 239000003102 growth factor Substances 0.000 description 6
• 229920000669 heparin Polymers 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 6
• 230000005855 radiation Effects 0.000 description 6
• 235000021283 resveratrol Nutrition 0.000 description 6
• 229940016667 resveratrol Drugs 0.000 description 6
• 210000003491 skin Anatomy 0.000 description 6
• 239000003053 toxin Substances 0.000 description 6
• 231100000765 toxin Toxicity 0.000 description 6
• 108700012359 toxins Proteins 0.000 description 6
• 239000013598 vector Substances 0.000 description 6
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 5
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
• 241000283690 Bos taurus Species 0.000 description 5
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 5
• 206010053567 Coagulopathies Diseases 0.000 description 5
• 241000206602 Eukaryota Species 0.000 description 5
• 108010033040 Histones Proteins 0.000 description 5
• 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 5
• 101000709248 Homo sapiens NAD-dependent protein deacetylase sirtuin-7 Proteins 0.000 description 5
• 101000863629 Homo sapiens NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Proteins 0.000 description 5
• 241000725303 Human immunodeficiency virus Species 0.000 description 5
• 208000004044 Hypesthesia Diseases 0.000 description 5
• 208000028389 Nerve injury Diseases 0.000 description 5
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 210000004958 brain cell Anatomy 0.000 description 5
• 210000005013 brain tissue Anatomy 0.000 description 5
• 239000000480 calcium channel blocker Substances 0.000 description 5
• 125000004432 carbon atom Chemical group C* 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 239000002327 cardiovascular agent Substances 0.000 description 5
• 229940125692 cardiovascular agent Drugs 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 230000007850 degeneration Effects 0.000 description 5
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 5
• 230000004064 dysfunction Effects 0.000 description 5
• 210000003414 extremity Anatomy 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 230000030279 gene silencing Effects 0.000 description 5
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 5
• 229940088597 hormone Drugs 0.000 description 5
• 239000005556 hormone Substances 0.000 description 5
• 102000055034 human SIRT4 Human genes 0.000 description 5
• 102000055198 human SIRT5 Human genes 0.000 description 5
• 102000049192 human SIRT6 Human genes 0.000 description 5
• 208000034783 hypoesthesia Diseases 0.000 description 5
• 230000007774 longterm Effects 0.000 description 5
• 230000002503 metabolic effect Effects 0.000 description 5
• 239000002207 metabolite Substances 0.000 description 5
• 201000005518 mononeuropathy Diseases 0.000 description 5
• 230000008764 nerve damage Effects 0.000 description 5
• 231100000862 numbness Toxicity 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 231100001274 therapeutic index Toxicity 0.000 description 5
• RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 5
• 229960001722 verapamil Drugs 0.000 description 5
• 229960003048 vinblastine Drugs 0.000 description 5
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 5
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
• 101710170757 Acidic leucine-rich nuclear phosphoprotein 32 family member A Proteins 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 4
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
• 206010012289 Dementia Diseases 0.000 description 4
• 208000016192 Demyelinating disease Diseases 0.000 description 4
• 206010012305 Demyelination Diseases 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 208000032928 Dyslipidaemia Diseases 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• 241000282326 Felis catus Species 0.000 description 4
• DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 4
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• 208000017170 Lipid metabolism disease Diseases 0.000 description 4
• 108010042046 Mitochondrial processing peptidase Proteins 0.000 description 4
• 102000006386 Myelin Proteins Human genes 0.000 description 4
• 108010083674 Myelin Proteins Proteins 0.000 description 4
• 206010028851 Necrosis Diseases 0.000 description 4
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
• 229930012538 Paclitaxel Natural products 0.000 description 4
• 241001494479 Pecora Species 0.000 description 4
• 102000013275 Somatomedins Human genes 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 4
• 206010053648 Vascular occlusion Diseases 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
• 210000001789 adipocyte Anatomy 0.000 description 4
• 230000036528 appetite Effects 0.000 description 4
• 210000001367 artery Anatomy 0.000 description 4
• 210000000601 blood cell Anatomy 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 235000020934 caloric restriction Nutrition 0.000 description 4
• 230000002490 cerebral effect Effects 0.000 description 4
• 229960003020 cilnidipine Drugs 0.000 description 4
• 229940000425 combination drug Drugs 0.000 description 4
• 229960000640 dactinomycin Drugs 0.000 description 4
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
• 229960000975 daunorubicin Drugs 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 239000002934 diuretic Substances 0.000 description 4
• 229940030606 diuretics Drugs 0.000 description 4
• 235000019441 ethanol Nutrition 0.000 description 4
• 208000030533 eye disease Diseases 0.000 description 4
• 239000003527 fibrinolytic agent Substances 0.000 description 4
• 229960000449 flecainide Drugs 0.000 description 4
• 229960002897 heparin Drugs 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 244000144972 livestock Species 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 208000030159 metabolic disease Diseases 0.000 description 4
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
• 229960001156 mitoxantrone Drugs 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 210000005012 myelin Anatomy 0.000 description 4
• 230000017074 necrotic cell death Effects 0.000 description 4
• 230000001537 neural effect Effects 0.000 description 4
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
• 229960001597 nifedipine Drugs 0.000 description 4
• 229960001592 paclitaxel Drugs 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
• REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 4
• 229960000244 procainamide Drugs 0.000 description 4
• 229960003712 propranolol Drugs 0.000 description 4
• 229940044601 receptor agonist Drugs 0.000 description 4
• 239000000018 receptor agonist Substances 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 230000011514 reflex Effects 0.000 description 4
• 230000035807 sensation Effects 0.000 description 4
• 235000019615 sensations Nutrition 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 4
• 208000021331 vascular occlusion disease Diseases 0.000 description 4
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 3
• PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 3
• MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 3
• UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 3
• UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 3
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 3
• UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 3
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
• RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 3
• 239000005541 ACE inhibitor Substances 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000000044 Amnesia Diseases 0.000 description 3
• 108010058207 Anistreplase Proteins 0.000 description 3
• 102000007372 Ataxin-1 Human genes 0.000 description 3
• 108010032963 Ataxin-1 Proteins 0.000 description 3
• 206010061666 Autonomic neuropathy Diseases 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 108010006654 Bleomycin Proteins 0.000 description 3
• 201000004569 Blindness Diseases 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 3
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
• 108010069514 Cyclic Peptides Proteins 0.000 description 3
• 102000001189 Cyclic Peptides Human genes 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• 230000033616 DNA repair Effects 0.000 description 3
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
• 108010049003 Fibrinogen Proteins 0.000 description 3
• 102000008946 Fibrinogen Human genes 0.000 description 3
• 208000002705 Glucose Intolerance Diseases 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• 208000031886 HIV Infections Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 206010024229 Leprosy Diseases 0.000 description 3
• 102000016267 Leptin Human genes 0.000 description 3
• 108010092277 Leptin Proteins 0.000 description 3
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
• 206010049287 Lipodystrophy acquired Diseases 0.000 description 3
• 102400001283 Long-acting natriuretic peptide Human genes 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 208000002720 Malnutrition Diseases 0.000 description 3
• 208000026139 Memory disease Diseases 0.000 description 3
• 229930192392 Mitomycin Natural products 0.000 description 3
• 102000010909 Monoamine Oxidase Human genes 0.000 description 3
• 108010062431 Monoamine oxidase Proteins 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 208000010428 Muscle Weakness Diseases 0.000 description 3
• 206010028372 Muscular weakness Diseases 0.000 description 3
• IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
• 206010029240 Neuritis Diseases 0.000 description 3
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
• 239000012661 PARP inhibitor Substances 0.000 description 3
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010060862 Prostate cancer Diseases 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 206010040021 Sensory abnormalities Diseases 0.000 description 3
• 108010041216 Sirtuin 2 Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 108010023197 Streptokinase Proteins 0.000 description 3
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
• 108010000499 Thromboplastin Proteins 0.000 description 3
• 102000002262 Thromboplastin Human genes 0.000 description 3
• FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 3
• RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 3
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
• 206010057469 Vascular stenosis Diseases 0.000 description 3
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 3
• 229960002122 acebutolol Drugs 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000000304 alkynyl group Chemical group 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 3
• 229960000528 amlodipine Drugs 0.000 description 3
• 229960001220 amsacrine Drugs 0.000 description 3
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 3
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
• 230000001028 anti-proliverative effect Effects 0.000 description 3
• 229940125708 antidiabetic agent Drugs 0.000 description 3
• 239000003472 antidiabetic agent Substances 0.000 description 3
• 229940127218 antiplatelet drug Drugs 0.000 description 3
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
• 229950010731 arotinolol Drugs 0.000 description 3
• BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 3
• 210000002565 arteriole Anatomy 0.000 description 3
• 229960002274 atenolol Drugs 0.000 description 3
• 230000003376 axonal effect Effects 0.000 description 3
• 230000007845 axonopathy Effects 0.000 description 3
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 3
• 229960003665 bepridil Drugs 0.000 description 3
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
• 230000036765 blood level Effects 0.000 description 3
• 229960001035 bopindolol Drugs 0.000 description 3
• 229960002092 busulfan Drugs 0.000 description 3
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
• 229940127093 camptothecin Drugs 0.000 description 3
• 229960000830 captopril Drugs 0.000 description 3
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 3
• 229960004562 carboplatin Drugs 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 208000015114 central nervous system disease Diseases 0.000 description 3
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
• 229960004630 chlorambucil Drugs 0.000 description 3
• 235000012000 cholesterol Nutrition 0.000 description 3
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
• 229960000876 cinnarizine Drugs 0.000 description 3
• DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 229960002768 dipyridamole Drugs 0.000 description 3
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
• 229960003668 docetaxel Drugs 0.000 description 3
• 239000002158 endotoxin Substances 0.000 description 3
• 229960001904 epirubicin Drugs 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
• 229960003580 felodipine Drugs 0.000 description 3
• 229940012952 fibrinogen Drugs 0.000 description 3
• 229960000326 flunarizine Drugs 0.000 description 3
• SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 3
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
• 229960003883 furosemide Drugs 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 229960003711 glyceryl trinitrate Drugs 0.000 description 3
• 125000001188 haloalkyl group Chemical group 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 210000002216 heart Anatomy 0.000 description 3
• 102000050401 human SIRT2 Human genes 0.000 description 3
• 102000044649 human SIRT7 Human genes 0.000 description 3
• 238000009396 hybridization Methods 0.000 description 3
• 229960002003 hydrochlorothiazide Drugs 0.000 description 3
• 201000001421 hyperglycemia Diseases 0.000 description 3
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
• 201000008980 hyperinsulinism Diseases 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 229960004768 irinotecan Drugs 0.000 description 3
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
• 229960004194 lidocaine Drugs 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 208000006132 lipodystrophy Diseases 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 230000001071 malnutrition Effects 0.000 description 3
• 235000000824 malnutrition Nutrition 0.000 description 3
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
• 229960001924 melphalan Drugs 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 230000006984 memory degeneration Effects 0.000 description 3
• 208000023060 memory loss Diseases 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 229960004857 mitomycin Drugs 0.000 description 3
• 210000002161 motor neuron Anatomy 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 229960000715 nimodipine Drugs 0.000 description 3
• 229960005425 nitrendipine Drugs 0.000 description 3
• 208000015380 nutritional deficiency disease Diseases 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 208000027232 peripheral nervous system disease Diseases 0.000 description 3
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 3
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 229960001404 quinidine Drugs 0.000 description 3
• 229940044551 receptor antagonist Drugs 0.000 description 3
• 239000002464 receptor antagonist Substances 0.000 description 3
• 230000007115 recruitment Effects 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
• 230000009758 senescence Effects 0.000 description 3
• 230000001953 sensory effect Effects 0.000 description 3
• 101150084733 sir-2.1 gene Proteins 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229960002370 sotalol Drugs 0.000 description 3
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 3
• 229960005202 streptokinase Drugs 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
• 229960001278 teniposide Drugs 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 239000003451 thiazide diuretic agent Substances 0.000 description 3
• 229960000103 thrombolytic agent Drugs 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 229960001288 triamterene Drugs 0.000 description 3
• 229960005356 urokinase Drugs 0.000 description 3
• 229940124549 vasodilator Drugs 0.000 description 3
• 239000003071 vasodilator agent Substances 0.000 description 3
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 3
• 229960004355 vindesine Drugs 0.000 description 3
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 3
• 229960000237 vorinostat Drugs 0.000 description 3
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
• HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
• KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
• VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 2
• CEMAWMOMDPGJMB-CYBMUJFWSA-N (2r)-1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-CYBMUJFWSA-N 0.000 description 2
• NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 2
• BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 2
• JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 2
• MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
• FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 description 2
• COAWNPJQKJEHPG-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 COAWNPJQKJEHPG-UHFFFAOYSA-N 0.000 description 2
• NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 2
• VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 2
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
• NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 2
• CDMAMPBHUVBTRZ-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(6-methyl-1h-benzimidazol-2-yl)propan-1-one Chemical compound N1C2=CC(C)=CC=C2N=C1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 CDMAMPBHUVBTRZ-UHFFFAOYSA-N 0.000 description 2
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
• LAMQVIQMVKWXOC-UHFFFAOYSA-N 4-methyl-n-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCOCC1 LAMQVIQMVKWXOC-UHFFFAOYSA-N 0.000 description 2
• OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
• RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• HUBVOBVRQANNOY-UHFFFAOYSA-N 6-[4-(1-methylpyrrolidin-3-yl)oxy-2-propan-2-ylphenyl]pyridin-2-amine Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(C(C)C)=CC=1OC1CCN(C)C1 HUBVOBVRQANNOY-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 229940098747 AMPA receptor antagonist Drugs 0.000 description 2
• 208000007848 Alcoholism Diseases 0.000 description 2
• 206010002388 Angina unstable Diseases 0.000 description 2
• 229940123413 Angiotensin II antagonist Drugs 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 108010027612 Batroxobin Proteins 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
• 239000002083 C09CA01 - Losartan Substances 0.000 description 2
• 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
• 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
• 241000282465 Canis Species 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 108091006146 Channels Proteins 0.000 description 2
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 206010008616 Cholecystitis and cholelithiasis Diseases 0.000 description 2
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000019736 Cranial nerve disease Diseases 0.000 description 2
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 206010067276 Cytotoxic oedema Diseases 0.000 description 2
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
• 206010012335 Dependence Diseases 0.000 description 2
• 108010002156 Depsipeptides Proteins 0.000 description 2
• DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• 240000001879 Digitalis lutea Species 0.000 description 2
• WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 2
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
• 206010014498 Embolic stroke Diseases 0.000 description 2
• 108010061435 Enalapril Proteins 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 102000010911 Enzyme Precursors Human genes 0.000 description 2
• 108010062466 Enzyme Precursors Proteins 0.000 description 2
• YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 108010014173 Factor X Proteins 0.000 description 2
• 241000282324 Felis Species 0.000 description 2
• 102000009123 Fibrin Human genes 0.000 description 2
• 108010073385 Fibrin Proteins 0.000 description 2
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 description 2
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
• PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 description 2
• 208000031448 Genomic Instability Diseases 0.000 description 2
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
• 229930186217 Glycolipid Natural products 0.000 description 2
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
• 108010069236 Goserelin Proteins 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 102000015779 HDL Lipoproteins Human genes 0.000 description 2
• 108010010234 HDL Lipoproteins Proteins 0.000 description 2
• 208000037357 HIV infectious disease Diseases 0.000 description 2
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
• 102000006947 Histones Human genes 0.000 description 2
• OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 2
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
• 108010007859 Lisinopril Proteins 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 208000037093 Menstruation Disturbances Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 2
• 102100026934 Mitochondrial intermediate peptidase Human genes 0.000 description 2
• 108010047660 Mitochondrial intermediate peptidase Proteins 0.000 description 2
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
• 102100034376 NAD-dependent protein deacetylase sirtuin-7 Human genes 0.000 description 2
• 241000244206 Nematoda Species 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
• FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 2
• 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
• 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 2
• 239000000006 Nitroglycerin Substances 0.000 description 2
• KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 2
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 108010016731 PPAR gamma Proteins 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
• 206010034719 Personality change Diseases 0.000 description 2
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• HRSANNODOVBCST-UHFFFAOYSA-N Pronethalol Chemical compound C1=CC=CC2=CC(C(O)CNC(C)C)=CC=C21 HRSANNODOVBCST-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• 108010094028 Prothrombin Proteins 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• 206010040030 Sensory loss Diseases 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 229940100389 Sulfonylurea Drugs 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
• 108090000190 Thrombin Proteins 0.000 description 2
• 206010043647 Thrombotic Stroke Diseases 0.000 description 2
• 206010056697 Tissue anoxia Diseases 0.000 description 2
• GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• 208000007814 Unstable Angina Diseases 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• GYKFWCDBQAFCLJ-RTWAWAEBSA-N [(2s,3s)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=C(Cl)C=C2S1 GYKFWCDBQAFCLJ-RTWAWAEBSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
• 229930183665 actinomycin Natural products 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• 229960005305 adenosine Drugs 0.000 description 2
• 210000000577 adipose tissue Anatomy 0.000 description 2
• 230000011759 adipose tissue development Effects 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
• 125000005336 allyloxy group Chemical group 0.000 description 2
• 229960000473 altretamine Drugs 0.000 description 2
• 229960003437 aminoglutethimide Drugs 0.000 description 2
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
• IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 2
• 229960005260 amiodarone Drugs 0.000 description 2
• 229960000836 amitriptyline Drugs 0.000 description 2
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
• LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 description 2
• 229950010351 amosulalol Drugs 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
• 229940045799 anthracyclines and related substance Drugs 0.000 description 2
• 239000004004 anti-anginal agent Substances 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 239000000883 anti-obesity agent Substances 0.000 description 2
• 229940127219 anticoagulant drug Drugs 0.000 description 2
• 230000010100 anticoagulation Effects 0.000 description 2
• 239000001961 anticonvulsive agent Substances 0.000 description 2
• 239000002220 antihypertensive agent Substances 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 239000003443 antiviral agent Substances 0.000 description 2
• 108010082820 apicidin Proteins 0.000 description 2
• 229930186608 apicidin Natural products 0.000 description 2
• 230000004597 appetite gain Effects 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 210000001130 astrocyte Anatomy 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000002567 autonomic effect Effects 0.000 description 2
• 210000003403 autonomic nervous system Anatomy 0.000 description 2
• FYJJXENSONZJRG-UHFFFAOYSA-N bencyclane Chemical compound C=1C=CC=CC=1CC1(OCCCN(C)C)CCCCCC1 FYJJXENSONZJRG-UHFFFAOYSA-N 0.000 description 2
• 229960000945 bencyclane Drugs 0.000 description 2
• 229960003515 bendroflumethiazide Drugs 0.000 description 2
• HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 2
• QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 2
• 229960004916 benidipine Drugs 0.000 description 2
• 229940054066 benzamide antipsychotics Drugs 0.000 description 2
• 150000003936 benzamides Chemical class 0.000 description 2
• 125000005605 benzo group Chemical group 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 2
• 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 2
• 229960004324 betaxolol Drugs 0.000 description 2
• NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 2
• 229960000997 bicalutamide Drugs 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 2
• 229960002781 bisoprolol Drugs 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 230000003925 brain function Effects 0.000 description 2
• 201000007293 brain stem infarction Diseases 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
• 229960002802 bromocriptine Drugs 0.000 description 2
• MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 2
• 229960004064 bumetanide Drugs 0.000 description 2
• VCVQSRCYSKKPBA-UHFFFAOYSA-N bunitrolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1C#N VCVQSRCYSKKPBA-UHFFFAOYSA-N 0.000 description 2
• 229950008581 bunitrolol Drugs 0.000 description 2
• AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 description 2
• NMBNQRJDEPOXCP-UHFFFAOYSA-N butofilolol Chemical compound CCCC(=O)C1=CC(F)=CC=C1OCC(O)CNC(C)(C)C NMBNQRJDEPOXCP-UHFFFAOYSA-N 0.000 description 2
• 229950009191 butofilolol Drugs 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 235000020827 calorie restriction Nutrition 0.000 description 2
• 229960004117 capecitabine Drugs 0.000 description 2
• BQXQGZPYHWWCEB-UHFFFAOYSA-N carazolol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 description 2
• 229960004634 carazolol Drugs 0.000 description 2
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
• 229960000623 carbamazepine Drugs 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 239000000496 cardiotonic agent Substances 0.000 description 2
• LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 2
• 229960001222 carteolol Drugs 0.000 description 2
• 229960004195 carvedilol Drugs 0.000 description 2
• NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
• 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 238000002659 cell therapy Methods 0.000 description 2
• 201000004559 cerebral degeneration Diseases 0.000 description 2
• UWCBNAVPISMFJZ-UHFFFAOYSA-N cetamolol Chemical compound CNC(=O)COC1=CC=CC=C1OCC(O)CNC(C)(C)C UWCBNAVPISMFJZ-UHFFFAOYSA-N 0.000 description 2
• 229950003205 cetamolol Drugs 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 230000002113 chemopreventative effect Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 229960002155 chlorothiazide Drugs 0.000 description 2
• 201000001883 cholelithiasis Diseases 0.000 description 2
• 239000000544 cholinesterase inhibitor Substances 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 229960002436 cladribine Drugs 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 229950000308 clentiazem Drugs 0.000 description 2
• 229960002896 clonidine Drugs 0.000 description 2
• 229960003009 clopidogrel Drugs 0.000 description 2
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 230000015271 coagulation Effects 0.000 description 2
• 238000005345 coagulation Methods 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 229940124558 contraceptive agent Drugs 0.000 description 2
• 239000003433 contraceptive agent Substances 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 229960003843 cyproterone Drugs 0.000 description 2
• DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 2
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
• 230000002354 daily effect Effects 0.000 description 2
• WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 2
• 229960005227 delapril Drugs 0.000 description 2
• 230000003210 demyelinating effect Effects 0.000 description 2
• DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 2
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
• 229960000648 digitoxin Drugs 0.000 description 2
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
• 229960005156 digoxin Drugs 0.000 description 2
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
• LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 2
• UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 2
• 229960001066 disopyramide Drugs 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 229940052760 dopamine agonists Drugs 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 229950003102 efonidipine Drugs 0.000 description 2
• 230000002996 emotional effect Effects 0.000 description 2
• 229960000873 enalapril Drugs 0.000 description 2
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
• 229960000610 enoxaparin Drugs 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 229960002711 epanolol Drugs 0.000 description 2
• XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
• 229960003745 esmolol Drugs 0.000 description 2
• AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 229940012426 factor x Drugs 0.000 description 2
• 208000037957 feline spongiform encephalopathy Diseases 0.000 description 2
• 229960002602 fendiline Drugs 0.000 description 2
• 229950003499 fibrin Drugs 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 239000004052 folic acid antagonist Substances 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
• 208000001130 gallstones Diseases 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• 229940045109 genistein Drugs 0.000 description 2
• 235000006539 genistein Nutrition 0.000 description 2
• TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
• ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
• 229940097043 glucuronic acid Drugs 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 229960002913 goserelin Drugs 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 230000009931 harmful effect Effects 0.000 description 2
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
• 229960002474 hydralazine Drugs 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 229960000908 idarubicin Drugs 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• 229960004801 imipramine Drugs 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 2
• 229950008838 indenolol Drugs 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 208000000509 infertility Diseases 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• 231100000535 infertility Toxicity 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
• 229960002198 irbesartan Drugs 0.000 description 2
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
• 229960002479 isosorbide Drugs 0.000 description 2
• 229960004427 isradipine Drugs 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 229960001632 labetalol Drugs 0.000 description 2
• 210000002414 leg Anatomy 0.000 description 2
• 229940039781 leptin Drugs 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 230000037356 lipid metabolism Effects 0.000 description 2
• 229920006008 lipopolysaccharide Polymers 0.000 description 2
• 229960002394 lisinopril Drugs 0.000 description 2
• CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 229960004773 losartan Drugs 0.000 description 2
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 229960003963 manidipine Drugs 0.000 description 2
• ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 235000013372 meat Nutrition 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
• 229960001786 megestrol Drugs 0.000 description 2
• JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 2
• 231100000544 menstrual irregularity Toxicity 0.000 description 2
• 229960003134 mepindolol Drugs 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 229960001428 mercaptopurine Drugs 0.000 description 2
• 239000003475 metalloproteinase inhibitor Substances 0.000 description 2
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
• VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 2
• BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 2
• 229960002704 metipranolol Drugs 0.000 description 2
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
• 229960002237 metoprolol Drugs 0.000 description 2
• 229960003404 mexiletine Drugs 0.000 description 2
• 229960004438 mibefradil Drugs 0.000 description 2
• 210000004088 microvessel Anatomy 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 229960000350 mitotane Drugs 0.000 description 2
• 201000000585 muscular atrophy Diseases 0.000 description 2
• 210000003007 myelin sheath Anatomy 0.000 description 2
• PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
• OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 description 2
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
• 229960004255 nadolol Drugs 0.000 description 2
• 229960004501 nadoxolol Drugs 0.000 description 2
• UPZVYDSBLFNMLK-UHFFFAOYSA-N nadoxolol Chemical compound C1=CC=C2C(OCC(O)CC(/N)=N/O)=CC=CC2=C1 UPZVYDSBLFNMLK-UHFFFAOYSA-N 0.000 description 2
• 210000004126 nerve fiber Anatomy 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 230000016273 neuron death Effects 0.000 description 2
• 229960001783 nicardipine Drugs 0.000 description 2
• 229960002497 nicorandil Drugs 0.000 description 2
• LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 2
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 2
• 229960002653 nilutamide Drugs 0.000 description 2
• 229960005366 nilvadipine Drugs 0.000 description 2
• 229950000754 nipradilol Drugs 0.000 description 2
• 229960000227 nisoldipine Drugs 0.000 description 2
• 239000002840 nitric oxide donor Substances 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 2
• 229950006344 nocodazole Drugs 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 208000001797 obstructive sleep apnea Diseases 0.000 description 2
• 230000008816 organ damage Effects 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
• 229960001756 oxaliplatin Drugs 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
• 229940046231 pamidronate Drugs 0.000 description 2
• XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
• 229960002296 paroxetine Drugs 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
• 229950009215 phenylbutanoic acid Drugs 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229960002508 pindolol Drugs 0.000 description 2
• PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 229960001289 prazosin Drugs 0.000 description 2
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
• 201000009104 prediabetes syndrome Diseases 0.000 description 2
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
• 229960000624 procarbazine Drugs 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 229950000992 pronetalol Drugs 0.000 description 2
• JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
• 229960001455 quinapril Drugs 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 235000020095 red wine Nutrition 0.000 description 2
• 230000009933 reproductive health Effects 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• SOEDEYVDCDYMMH-UHFFFAOYSA-N robinetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 SOEDEYVDCDYMMH-UHFFFAOYSA-N 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000000952 serotonin receptor agonist Substances 0.000 description 2
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
• 150000004666 short chain fatty acids Chemical class 0.000 description 2
• 235000021391 short chain fatty acids Nutrition 0.000 description 2
• 101150006137 sir gene Proteins 0.000 description 2
• 101150089009 sir2 gene Proteins 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
• 210000004003 subcutaneous fat Anatomy 0.000 description 2
• 125000003107 substituted aryl group Chemical group 0.000 description 2
• 229960005314 suramin Drugs 0.000 description 2
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
• 229960001693 terazosin Drugs 0.000 description 2
• 229960003604 testosterone Drugs 0.000 description 2
• 229960001196 thiotepa Drugs 0.000 description 2
• 210000000115 thoracic cavity Anatomy 0.000 description 2
• 229960004072 thrombin Drugs 0.000 description 2
• 229960005001 ticlopidine Drugs 0.000 description 2
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
• 229960004605 timolol Drugs 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 229960002872 tocainide Drugs 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 239000012049 topical pharmaceutical composition Substances 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 229960000363 trapidil Drugs 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 230000008736 traumatic injury Effects 0.000 description 2
• 229960001727 tretinoin Drugs 0.000 description 2
• 150000003626 triacylglycerols Chemical class 0.000 description 2
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
• 229960000604 valproic acid Drugs 0.000 description 2
• 229960004699 valsartan Drugs 0.000 description 2
• SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
• 229950005577 vesnarinone Drugs 0.000 description 2
• RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
• 229960002066 vinorelbine Drugs 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 229960005080 warfarin Drugs 0.000 description 2
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
• WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
• 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
• VXLBSYHAEKDUSU-JXMROGBWSA-N (2e)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine Chemical compound NC\C(=C\F)CCC1=CC=C(F)C=C1 VXLBSYHAEKDUSU-JXMROGBWSA-N 0.000 description 1
• NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 description 1
• YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
• ZVEMACCDKBQNGX-KALODSIISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid Chemical compound CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N ZVEMACCDKBQNGX-KALODSIISA-N 0.000 description 1
• WSYRBHQWMXTCHQ-SFIKJRKMSA-N (2s)-n-[(2r)-1-[[(2s)-1-[[(2r)-1-[[(2r)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-[[( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 WSYRBHQWMXTCHQ-SFIKJRKMSA-N 0.000 description 1
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• WJBHHTPFTVKZCV-CVEARBPZSA-N (3S,4R)-3-hydroxy-2,2-dimethyl-4-[(3-oxo-1-cyclopentenyl)oxy]-3,4-dihydro-2H-1-benzopyran-6-carbonitrile Chemical compound O([C@@H]1C2=CC(=CC=C2OC([C@H]1O)(C)C)C#N)C1=CC(=O)CC1 WJBHHTPFTVKZCV-CVEARBPZSA-N 0.000 description 1
• DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
• JGYVZUCCBOVDJE-MJGOQNOKSA-N (3r,4s)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]-3,4-dihydro-2h-chromene-4,7-diol Chemical compound C1CN([C@H]2[C@H](C3=CC=C(O)C=C3OC2)O)CCC1(O)C1=CC=C(F)C=C1 JGYVZUCCBOVDJE-MJGOQNOKSA-N 0.000 description 1
• NDYMQOUYJJXCKJ-UHFFFAOYSA-N (4-fluorophenyl)-morpholin-4-ylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CCOCC1 NDYMQOUYJJXCKJ-UHFFFAOYSA-N 0.000 description 1
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
• JTVLYHXMPUSZIT-VKAVYKQESA-N (6z)-6-[butylamino-(2-chlorophenyl)methylidene]-4-chlorocyclohexa-2,4-dien-1-one Chemical compound C=1C=CC=C(Cl)C=1C(/NCCCC)=C1\C=C(Cl)C=CC1=O JTVLYHXMPUSZIT-VKAVYKQESA-N 0.000 description 1
• GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
• QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 1
• BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
• VKHHHFPQQRCPJG-UHFFFAOYSA-N 1-(1,3-benzoxazol-6-yl)-3-(1-benzylpiperidin-4-yl)propan-1-one Chemical compound C=1C=C2N=COC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 VKHHHFPQQRCPJG-UHFFFAOYSA-N 0.000 description 1
• GFKZCFJJXOEGLX-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)-3-(1-benzylpiperidin-4-yl)propan-1-one Chemical compound C=1C2=CC=CC=C2OC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 GFKZCFJJXOEGLX-UHFFFAOYSA-N 0.000 description 1
• SGUUCMAJRUJNIB-UHFFFAOYSA-N 1-(1-benzofuran-5-yl)-3-(1-benzylpiperidin-4-yl)propan-1-one Chemical compound C=1C=C2OC=CC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 SGUUCMAJRUJNIB-UHFFFAOYSA-N 0.000 description 1
• VASIMCDSZNZFQN-UHFFFAOYSA-N 1-(1-benzothiophen-5-yl)-3-(1-benzylpiperidin-4-yl)propan-1-one Chemical compound C=1C=C2SC=CC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 VASIMCDSZNZFQN-UHFFFAOYSA-N 0.000 description 1
• NXSUZXBPENMLPO-UHFFFAOYSA-N 1-(5-amino-1h-indol-2-yl)-3-(1-benzylpiperidin-4-yl)propan-1-one Chemical compound C=1C2=CC(N)=CC=C2NC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 NXSUZXBPENMLPO-UHFFFAOYSA-N 0.000 description 1
• CAGLIAGCBUSTQI-MGPUTAFESA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1=C(O)C(OC)=CC([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=C1 CAGLIAGCBUSTQI-MGPUTAFESA-N 0.000 description 1
• QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 1
• NJJPKIPOZSWUHV-QGZVFWFLSA-N 1-[(2r)-2-(1,3-dioxolan-2-yl)-2-methyl-6-nitrochromen-4-yl]pyrrolidin-2-one Chemical compound O([C@@](C=1)(C)C2OCCO2)C2=CC=C([N+]([O-])=O)C=C2C=1N1CCCC1=O NJJPKIPOZSWUHV-QGZVFWFLSA-N 0.000 description 1
• KDLHCMREKKHEOX-UHFFFAOYSA-N 1-[1-(benzenesulfonyl)-6-methylindol-2-yl]-3-(1-benzylpiperidin-4-yl)propan-1-one Chemical compound C=1C=CC=CC=1S(=O)(=O)N1C2=CC(C)=CC=C2C=C1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 KDLHCMREKKHEOX-UHFFFAOYSA-N 0.000 description 1
• GETNYSZHXJZOLF-RDRKJGRWSA-N 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-[(e)-3-phenylprop-2-enyl]piperazine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(C\C=C\C=2C=CC=CC=2)CC1 GETNYSZHXJZOLF-RDRKJGRWSA-N 0.000 description 1
• VDNMHYXXPPMHKJ-UHFFFAOYSA-N 1-[5-amino-1-(benzenesulfonyl)indol-2-yl]-3-(1-benzylpiperidin-4-yl)propan-1-one Chemical compound C=1C2=CC(N)=CC=C2N(S(=O)(=O)C=2C=CC=CC=2)C=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 VDNMHYXXPPMHKJ-UHFFFAOYSA-N 0.000 description 1
• IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 1
• JUDKOGFHZYMDMF-UHFFFAOYSA-N 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Chemical compound C1=2C=C(O)C(O)=CC=2CCNCC1C1=CC=CC=C1 JUDKOGFHZYMDMF-UHFFFAOYSA-N 0.000 description 1
• VTDIWMPYBAVEDY-UHFFFAOYSA-N 1-propylpiperidine Chemical compound CCCN1CCCCC1 VTDIWMPYBAVEDY-UHFFFAOYSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• BMWKJTDBSUHOAM-UHFFFAOYSA-N 2-(2,5-dimethylpyrrolidin-1-yl)-6-[2-propan-2-yl-4-(2-pyrrolidin-1-ylethoxy)phenyl]pyridine Chemical compound C=1C=C(C=2N=C(C=CC=2)N2C(CCC2C)C)C(C(C)C)=CC=1OCCN1CCCC1 BMWKJTDBSUHOAM-UHFFFAOYSA-N 0.000 description 1
• CCGIAEHSWFWXKX-UHFFFAOYSA-N 2-(6-aminopyridin-2-yl)-5-[2-(dimethylamino)ethoxy]phenol Chemical compound OC1=CC(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 CCGIAEHSWFWXKX-UHFFFAOYSA-N 0.000 description 1
• DEMLYXMVPJAVFU-UHFFFAOYSA-N 2-(chloromethyl)oxirane;2-methyl-1h-imidazole Chemical compound ClCC1CO1.CC1=NC=CN1 DEMLYXMVPJAVFU-UHFFFAOYSA-N 0.000 description 1
• OGGMQNTWQQMVST-UHFFFAOYSA-N 2-[4-(6-aminopyridin-2-yl)-3,5-dimethylphenoxy]acetamide Chemical compound CC1=CC(OCC(N)=O)=CC(C)=C1C1=CC=CC(N)=N1 OGGMQNTWQQMVST-UHFFFAOYSA-N 0.000 description 1
• HAGRICAMPFNRSN-UHFFFAOYSA-N 2-[4-(6-aminopyridin-2-yl)-3-methoxyphenoxy]-1-(2,2,6,6-tetramethylpiperidin-1-yl)ethanone Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OCC(=O)N1C(C)(C)CCCC1(C)C HAGRICAMPFNRSN-UHFFFAOYSA-N 0.000 description 1
• JYJLBJXGFVEHTQ-UHFFFAOYSA-N 2-[4-(6-aminopyridin-2-yl)-3-methoxyphenoxy]acetamide Chemical compound COC1=CC(OCC(N)=O)=CC=C1C1=CC=CC(N)=N1 JYJLBJXGFVEHTQ-UHFFFAOYSA-N 0.000 description 1
• UZHZLZHBXWXQRC-UHFFFAOYSA-N 2-[4-(6-aminopyridin-2-yl)-3-methoxyphenoxy]ethanol Chemical compound COC1=CC(OCCO)=CC=C1C1=CC=CC(N)=N1 UZHZLZHBXWXQRC-UHFFFAOYSA-N 0.000 description 1
• NYWSLZMTZNODJM-MCGDBQAWSA-N 2-[5-[(4e,20e)-35-butyl-19-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-10,12,14,16,18,22,26,30,34-nonahydroxy-3,5,21,33-tetramethyl-36-oxo-1-oxacyclohexatriaconta-4,20-dien-2-yl]-4-hydroxyhexyl]guanidine Chemical compound OC1CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(C(C)C(O)CCCN=C(N)N)OC(=O)C(CCCC)C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NYWSLZMTZNODJM-MCGDBQAWSA-N 0.000 description 1
• ZGLIFVFRIOKQLE-UHFFFAOYSA-N 2-[N-butyl-C-(2-chlorophenyl)carbonimidoyl]-4-chlorophenol Chemical compound C=1C(Cl)=CC=C(O)C=1C(=NCCCC)C1=CC=CC=C1Cl ZGLIFVFRIOKQLE-UHFFFAOYSA-N 0.000 description 1
• WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
• CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
• 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
• NMPLPABDEKPABN-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(1-ethyl-2-methylbenzimidazol-5-yl)propan-1-one Chemical compound C=1C=C2N(CC)C(C)=NC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 NMPLPABDEKPABN-UHFFFAOYSA-N 0.000 description 1
• CPQKZLNBCUOHCW-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(1h-indol-5-yl)propan-1-one Chemical compound C=1C=C2NC=CC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 CPQKZLNBCUOHCW-UHFFFAOYSA-N 0.000 description 1
• QLUXKUWFQAHCGM-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(1h-pyrrolo[3,2-c]pyridin-2-yl)propan-1-one Chemical compound C=1C2=CN=CC=C2NC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 QLUXKUWFQAHCGM-UHFFFAOYSA-N 0.000 description 1
• WUDBCFDOLSHYHH-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(2-methyl-1,3-benzothiazol-6-yl)propan-1-one Chemical compound C1=C2SC(C)=NC2=CC=C1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 WUDBCFDOLSHYHH-UHFFFAOYSA-N 0.000 description 1
• LTHKGHCYYOBVQU-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(2-methyl-3h-benzimidazol-5-yl)propan-1-one Chemical compound C=1C=C2NC(C)=NC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 LTHKGHCYYOBVQU-UHFFFAOYSA-N 0.000 description 1
• HVWVPJQXLNDOEK-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(2-phenyl-3h-benzimidazol-5-yl)propan-1-one Chemical compound C=1C=C2NC(C=3C=CC=CC=3)=NC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 HVWVPJQXLNDOEK-UHFFFAOYSA-N 0.000 description 1
• IKPRJUUNIIBINX-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(6-methoxy-1h-indol-2-yl)propan-1-one Chemical compound N1C2=CC(OC)=CC=C2C=C1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 IKPRJUUNIIBINX-UHFFFAOYSA-N 0.000 description 1
• DTRFPWSATAALIX-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(6-methyl-1,3-benzothiazol-2-yl)propan-1-one Chemical compound S1C2=CC(C)=CC=C2N=C1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 DTRFPWSATAALIX-UHFFFAOYSA-N 0.000 description 1
• TYQKHRFHWXGUQN-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-(6-methyl-1h-indol-2-yl)propan-1-one Chemical compound N1C2=CC(C)=CC=C2C=C1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 TYQKHRFHWXGUQN-UHFFFAOYSA-N 0.000 description 1
• BMSMKIFWFFMDMU-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-quinazolin-6-ylpropan-1-one Chemical compound C=1C=C2N=CN=CC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 BMSMKIFWFFMDMU-UHFFFAOYSA-N 0.000 description 1
• QVTWFJANNKSMNP-UHFFFAOYSA-N 3-(1-benzylpiperidin-4-yl)-1-quinolin-6-ylpropan-1-one Chemical compound C=1C=C2N=CC=CC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 QVTWFJANNKSMNP-UHFFFAOYSA-N 0.000 description 1
• KLWPBEWWHJTYDC-SNAWJCMRSA-N 3-[(e)-2-carboxyethenyl]benzoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(C(O)=O)=C1 KLWPBEWWHJTYDC-SNAWJCMRSA-N 0.000 description 1
• QMQQOVGCVPEGSA-UHFFFAOYSA-N 3-[2-(1-benzylpiperidin-4-yl)ethyl]-1,2-benzothiazole Chemical compound N=1SC2=CC=CC=C2C=1CCC(CC1)CCN1CC1=CC=CC=C1 QMQQOVGCVPEGSA-UHFFFAOYSA-N 0.000 description 1
• LLOAJMWVAODKLQ-UHFFFAOYSA-N 3-[2-(1-benzylpiperidin-4-yl)ethyl]-1,2-benzoxazol-6-amine Chemical compound N=1OC2=CC(N)=CC=C2C=1CCC(CC1)CCN1CC1=CC=CC=C1 LLOAJMWVAODKLQ-UHFFFAOYSA-N 0.000 description 1
• VFDQMJCSKFAKRY-UHFFFAOYSA-N 3-[2-(1-benzylpiperidin-4-yl)ethyl]-6-methoxy-1,2-benzoxazole Chemical compound N=1OC2=CC(OC)=CC=C2C=1CCC(CC1)CCN1CC1=CC=CC=C1 VFDQMJCSKFAKRY-UHFFFAOYSA-N 0.000 description 1
• ABZZRKAYYAWKGS-UHFFFAOYSA-N 3-[2-(1-benzylpiperidin-4-yl)ethyl]-n-phenyl-1,2-benzoxazol-6-amine Chemical compound C1CN(CC=2C=CC=CC=2)CCC1CCC(C1=CC=2)=NOC1=CC=2NC1=CC=CC=C1 ABZZRKAYYAWKGS-UHFFFAOYSA-N 0.000 description 1
• ZCDSKKMKDDRTCH-UHFFFAOYSA-N 3-[2-[4-(6-aminopyridin-2-yl)-3-ethoxyphenoxy]ethyl]-3-azabicyclo[3.1.0]hexan-6-amine Chemical compound CCOC1=CC(OCCN2CC3C(N)C3C2)=CC=C1C1=CC=CC(N)=N1 ZCDSKKMKDDRTCH-UHFFFAOYSA-N 0.000 description 1
• ZCCCYLUTZGLXIX-UHFFFAOYSA-N 3-[3-(6-aminopyridin-2-yl)-4-cyclopropylphenoxy]pyrrolidine-1-carboxylic acid Chemical compound NC1=CC=CC(C=2C(=CC=C(OC3CN(CC3)C(O)=O)C=2)C2CC2)=N1 ZCCCYLUTZGLXIX-UHFFFAOYSA-N 0.000 description 1
• AHQWJOIFLITGFD-UHFFFAOYSA-N 3-[4-(6-aminopyridin-2-yl)-3-methoxyphenoxy]azetidine-1-carboxylic acid Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OC1CN(C(O)=O)C1 AHQWJOIFLITGFD-UHFFFAOYSA-N 0.000 description 1
• ULMNLKIAEXTVOQ-UHFFFAOYSA-N 3-[4-(6-aminopyridin-2-yl)-3-methoxyphenoxy]pyrrolidine-1-carboxylic acid Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OC1CCN(C(O)=O)C1 ULMNLKIAEXTVOQ-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
• 125000001331 3-methylbutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
• QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
• 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 description 1
• 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
• VJPANQWIZQHGMJ-UHFFFAOYSA-N 4-(1-propyl-3,6-dihydro-2h-pyridin-5-yl)-1,3-thiazol-2-amine Chemical compound C1N(CCC)CCC=C1C1=CSC(N)=N1 VJPANQWIZQHGMJ-UHFFFAOYSA-N 0.000 description 1
• HDBIPPQYIYVHOK-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-cyclobutyl-2-propylphenol Chemical compound C1CCC1C=1C(CCC)=C(O)C=CC=1C1=CC=CC(N)=N1 HDBIPPQYIYVHOK-UHFFFAOYSA-N 0.000 description 1
• KMPIDOMSSJIINY-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-cyclobutylphenol Chemical compound NC1=CC=CC(C=2C(=CC(O)=CC=2)C2CCC2)=N1 KMPIDOMSSJIINY-UHFFFAOYSA-N 0.000 description 1
• NWBNXZXGFIIUIP-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-cyclopentylphenol Chemical compound NC1=CC=CC(C=2C(=CC(O)=CC=2)C2CCCC2)=N1 NWBNXZXGFIIUIP-UHFFFAOYSA-N 0.000 description 1
• GVUCVRXLDWFFPO-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-cyclopropylphenol Chemical compound NC1=CC=CC(C=2C(=CC(O)=CC=2)C2CC2)=N1 GVUCVRXLDWFFPO-UHFFFAOYSA-N 0.000 description 1
• FWXKPCHUSMDKJD-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-methoxyphenol Chemical compound COC1=CC(O)=CC=C1C1=CC=CC(N)=N1 FWXKPCHUSMDKJD-UHFFFAOYSA-N 0.000 description 1
• MRDLPBIVNATIBX-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-5-cyclobutyl-2-propylphenol Chemical compound C1CCC1C=1C=C(O)C(CCC)=CC=1C1=CC=CC(N)=N1 MRDLPBIVNATIBX-UHFFFAOYSA-N 0.000 description 1
• RHVZNUMCGSLHME-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-5-methoxy-2-propylphenol Chemical compound C1=C(O)C(CCC)=CC(C=2N=C(N)C=CC=2)=C1OC RHVZNUMCGSLHME-UHFFFAOYSA-N 0.000 description 1
• RUBSCPARMVJNKX-UHFFFAOYSA-N 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline;hydrochloride Chemical class Cl.C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C(N)C=C1 RUBSCPARMVJNKX-UHFFFAOYSA-N 0.000 description 1
• UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
• QSUSKMBNZQHHPA-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-ylimidazol-2-yl]but-3-yn-1-ol Chemical compound C=1C=CC=CC=1CCCN1C(C#CCCO)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 QSUSKMBNZQHHPA-UHFFFAOYSA-N 0.000 description 1
• NBOCQTNZUPTTEI-UHFFFAOYSA-N 4-[4-(hydrazinesulfonyl)phenoxy]benzenesulfonohydrazide Chemical compound C1=CC(S(=O)(=O)NN)=CC=C1OC1=CC=C(S(=O)(=O)NN)C=C1 NBOCQTNZUPTTEI-UHFFFAOYSA-N 0.000 description 1
• ZBRHTUMWSDPCMI-UHFFFAOYSA-N 4-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-4-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOCC1 ZBRHTUMWSDPCMI-UHFFFAOYSA-N 0.000 description 1
• PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
• SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical class OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• GSAHFRQIQURXHP-UHFFFAOYSA-N 5,6-diethoxy-2,3-dihydroinden-1-one Chemical compound C1=C(OCC)C(OCC)=CC2=C1C(=O)CC2 GSAHFRQIQURXHP-UHFFFAOYSA-N 0.000 description 1
• LKLNTTMWFRNYLE-UHFFFAOYSA-N 5,6-dihydrocyclopenta[f][1,3]benzodioxol-7-one Chemical compound C1=C2C(=O)CCC2=CC2=C1OCO2 LKLNTTMWFRNYLE-UHFFFAOYSA-N 0.000 description 1
• 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
• 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
• QOPRWBRNMPANKN-UHFFFAOYSA-N 5-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=C2C(=O)CCC2=C1 QOPRWBRNMPANKN-UHFFFAOYSA-N 0.000 description 1
• RWVIMCIPOAXUDG-UHFFFAOYSA-N 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C([N+]([O-])=O)=C2 RWVIMCIPOAXUDG-UHFFFAOYSA-N 0.000 description 1
• SWTJUTMEEFYPLU-UHFFFAOYSA-N 6-(5-ethyl-2-methoxy-4-piperidin-4-yloxyphenyl)pyridin-2-amine Chemical compound CCC1=CC(C=2N=C(N)C=CC=2)=C(OC)C=C1OC1CCNCC1 SWTJUTMEEFYPLU-UHFFFAOYSA-N 0.000 description 1
• AFMGEKOPFBWJAK-UHFFFAOYSA-N 6-[2,3-dimethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]pyridin-2-amine Chemical compound CC1=C(C)C(C=2N=C(N)C=CC=2)=CC=C1OCCN1CCCC1 AFMGEKOPFBWJAK-UHFFFAOYSA-N 0.000 description 1
• ORSKJLBQKIWWJP-UHFFFAOYSA-N 6-[2,5-dimethoxy-4-(1-methylpyrrolidin-3-yl)oxyphenyl]pyridin-2-amine Chemical compound COC1=CC(C=2N=C(N)C=CC=2)=C(OC)C=C1OC1CCN(C)C1 ORSKJLBQKIWWJP-UHFFFAOYSA-N 0.000 description 1
• SNEMDFXPJPJEGS-UHFFFAOYSA-N 6-[2,5-dimethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]pyridin-2-amine Chemical compound CC1=CC(C=2N=C(N)C=CC=2)=C(C)C=C1OCCN1CCCC1 SNEMDFXPJPJEGS-UHFFFAOYSA-N 0.000 description 1
• GZJBLGMQJZBCTR-UHFFFAOYSA-N 6-[2,5-dimethyl-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethoxy]phenyl]pyridin-2-amine Chemical compound CC1=CC(C=2N=C(N)C=CC=2)=C(C)C=C1OCCN(CC1)CCN1CCC1=CC=CC=C1 GZJBLGMQJZBCTR-UHFFFAOYSA-N 0.000 description 1
• RAALGBGFKBCULV-UHFFFAOYSA-N 6-[2,6-dimethyl-4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound C=1C(C)=C(C=2N=C(N)C=CC=2)C(C)=CC=1OCCN1CCOCC1 RAALGBGFKBCULV-UHFFFAOYSA-N 0.000 description 1
• WEKFUVNAPLGCMC-UHFFFAOYSA-N 6-[2,6-dimethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]pyridin-2-amine Chemical compound C=1C(C)=C(C=2N=C(N)C=CC=2)C(C)=CC=1OCCN1CCCC1 WEKFUVNAPLGCMC-UHFFFAOYSA-N 0.000 description 1
• JWWKACUQTXHARI-UHFFFAOYSA-N 6-[2,6-dimethyl-4-(3-piperidin-1-ylpropoxy)phenyl]pyridin-2-amine Chemical compound C=1C(C)=C(C=2N=C(N)C=CC=2)C(C)=CC=1OCCCN1CCCCC1 JWWKACUQTXHARI-UHFFFAOYSA-N 0.000 description 1
• BJAABLGUDWORDO-UHFFFAOYSA-N 6-[2,6-dimethyl-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]pyridin-2-amine Chemical compound C1CN(C)CCN1CCCOC1=CC(C)=C(C=2N=C(N)C=CC=2)C(C)=C1 BJAABLGUDWORDO-UHFFFAOYSA-N 0.000 description 1
• LSFSTXHTDKCSDO-UHFFFAOYSA-N 6-[2-cyclobutyl-4-[1-(dimethylamino)propan-2-yloxy]phenyl]pyridin-2-amine Chemical compound C1CCC1C1=CC(OC(CN(C)C)C)=CC=C1C1=CC=CC(N)=N1 LSFSTXHTDKCSDO-UHFFFAOYSA-N 0.000 description 1
• LRAZLMLMYYPNRJ-UHFFFAOYSA-N 6-[2-cyclopropyl-4-[1-(dimethylamino)propan-2-yloxy]phenyl]pyridin-2-amine Chemical compound C1CC1C1=CC(OC(CN(C)C)C)=CC=C1C1=CC=CC(N)=N1 LRAZLMLMYYPNRJ-UHFFFAOYSA-N 0.000 description 1
• DLMVQYGVFMFDTL-UHFFFAOYSA-N 6-[2-ethoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]pyridin-2-amine Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OCC)=CC=1OCCN1CCCC1 DLMVQYGVFMFDTL-UHFFFAOYSA-N 0.000 description 1
• PUXLUZKRUFSGIU-UHFFFAOYSA-N 6-[2-ethoxy-4-(3-methylbutoxy)phenyl]pyridin-2-amine Chemical compound CCOC1=CC(OCCC(C)C)=CC=C1C1=CC=CC(N)=N1 PUXLUZKRUFSGIU-UHFFFAOYSA-N 0.000 description 1
• RPRHCMJBLRDCJC-UHFFFAOYSA-N 6-[2-methoxy-4-(1-methylpiperidin-4-yl)oxyphenyl]pyridin-2-amine Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OC1CCN(C)CC1 RPRHCMJBLRDCJC-UHFFFAOYSA-N 0.000 description 1
• DEYFWGXTPWNADC-UHFFFAOYSA-N 6-[2-phenylethyl(propyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CC=C1 DEYFWGXTPWNADC-UHFFFAOYSA-N 0.000 description 1
• XEGCFXZBGQOSHJ-UHFFFAOYSA-N 6-[2-propan-2-yl-4-(2-pyrrolidin-1-ylethoxy)phenyl]pyridin-2-amine Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(C(C)C)=CC=1OCCN1CCCC1 XEGCFXZBGQOSHJ-UHFFFAOYSA-N 0.000 description 1
• YXHDZNNBOLTUMX-UHFFFAOYSA-N 6-[2-tert-butyl-4-[2-(dimethylamino)ethoxy]phenyl]pyridin-2-amine Chemical compound CC(C)(C)C1=CC(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 YXHDZNNBOLTUMX-UHFFFAOYSA-N 0.000 description 1
• NGWJUPGWCPOBNK-UHFFFAOYSA-N 6-[3-methoxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]pyridin-2-amine Chemical compound COC1=CC(C=2N=C(N)C=CC=2)=CC=C1OCCN1CCN(C)CC1 NGWJUPGWCPOBNK-UHFFFAOYSA-N 0.000 description 1
• ZJLGNJGBBFQURJ-UHFFFAOYSA-N 6-[3-methoxy-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethoxy]phenyl]pyridin-2-amine Chemical compound COC1=CC(C=2N=C(N)C=CC=2)=CC=C1OCCN(CC1)CCN1CCC1=CC=CC=C1 ZJLGNJGBBFQURJ-UHFFFAOYSA-N 0.000 description 1
• WIVOBEUVRNNKIO-UHFFFAOYSA-N 6-[4-(1-ethylpiperidin-4-yl)oxy-2-methoxyphenyl]pyridin-2-amine Chemical compound C1CN(CC)CCC1OC1=CC=C(C=2N=C(N)C=CC=2)C(OC)=C1 WIVOBEUVRNNKIO-UHFFFAOYSA-N 0.000 description 1
• BDXBIECUDLZEAU-UHFFFAOYSA-N 6-[4-(2-aminoethoxy)-2,6-dimethylphenyl]pyridin-2-amine Chemical compound CC1=CC(OCCN)=CC(C)=C1C1=CC=CC(N)=N1 BDXBIECUDLZEAU-UHFFFAOYSA-N 0.000 description 1
• KFRHEALMRJIAGJ-UHFFFAOYSA-N 6-[4-[(2-methyl-2-azabicyclo[2.2.1]heptan-5-yl)oxy]-2-propan-2-ylphenyl]pyridin-2-amine Chemical compound CC(C)C1=CC(OC2C3CC(N(C3)C)C2)=CC=C1C1=CC=CC(N)=N1 KFRHEALMRJIAGJ-UHFFFAOYSA-N 0.000 description 1
• IJBYTKFDMWTEFS-UHFFFAOYSA-N 6-[4-[2-(3,4-dihydro-1h-isoquinolin-2-yl)ethoxy]-2-methoxyphenyl]pyridin-2-amine Chemical compound COC1=CC(OCCN2CC3=CC=CC=C3CC2)=CC=C1C1=CC=CC(N)=N1 IJBYTKFDMWTEFS-UHFFFAOYSA-N 0.000 description 1
• WDJCFQUIQUMEED-UHFFFAOYSA-N 6-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethoxy]-3-methoxyphenyl]pyridin-2-amine Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CCOC(C(=C1)OC)=CC=C1C1=CC=CC(N)=N1 WDJCFQUIQUMEED-UHFFFAOYSA-N 0.000 description 1
• YVXYRAOPGJIRKJ-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-2,3-dimethylphenyl]pyridin-2-amine Chemical compound CC1=C(C)C(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 YVXYRAOPGJIRKJ-UHFFFAOYSA-N 0.000 description 1
• BINUUOSZFCUZSP-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-2,5-dimethylphenyl]pyridin-2-amine Chemical compound C1=C(C)C(OCCN(C)C)=CC(C)=C1C1=CC=CC(N)=N1 BINUUOSZFCUZSP-UHFFFAOYSA-N 0.000 description 1
• BKLYWBCAGXIOBD-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-2,6-dimethylphenyl]pyridin-2-amine Chemical compound CC1=CC(OCCN(C)C)=CC(C)=C1C1=CC=CC(N)=N1 BKLYWBCAGXIOBD-UHFFFAOYSA-N 0.000 description 1
• DTYUPHYOUWWLNO-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-2-methoxyphenyl]pyridin-2-amine Chemical compound COC1=CC(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 DTYUPHYOUWWLNO-UHFFFAOYSA-N 0.000 description 1
• PNGXBFZJSUYFFP-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-2-propoxyphenyl]pyridin-2-amine Chemical compound CCCOC1=CC(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 PNGXBFZJSUYFFP-UHFFFAOYSA-N 0.000 description 1
• SSCAXWVLIPFOPR-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-3-methoxyphenyl]pyridin-2-amine Chemical compound C1=C(OCCN(C)C)C(OC)=CC(C=2N=C(N)C=CC=2)=C1 SSCAXWVLIPFOPR-UHFFFAOYSA-N 0.000 description 1
• YYHAYQMSCVNTOG-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-5-ethoxy-2-methoxyphenyl]pyridin-2-amine Chemical compound C1=C(OCCN(C)C)C(OCC)=CC(C=2N=C(N)C=CC=2)=C1OC YYHAYQMSCVNTOG-UHFFFAOYSA-N 0.000 description 1
• BKULSIOVOCWIBT-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-5-ethyl-2-methoxyphenyl]pyridin-2-amine Chemical compound C1=C(OCCN(C)C)C(CC)=CC(C=2N=C(N)C=CC=2)=C1OC BKULSIOVOCWIBT-UHFFFAOYSA-N 0.000 description 1
• CFGJMSGCERXIDU-UHFFFAOYSA-N 6-[4-[2-[benzyl(methyl)amino]ethoxy]-2-methoxyphenyl]pyridin-2-amine Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OCCN(C)CC1=CC=CC=C1 CFGJMSGCERXIDU-UHFFFAOYSA-N 0.000 description 1
• UVVLXNKUCUXVRI-UHFFFAOYSA-N 6-[5-ethyl-2-methoxy-4-(1-methylpiperidin-4-yl)oxyphenyl]pyridin-2-amine Chemical compound CCC1=CC(C=2N=C(N)C=CC=2)=C(OC)C=C1OC1CCN(C)CC1 UVVLXNKUCUXVRI-UHFFFAOYSA-N 0.000 description 1
• TWEJJOTUOVZLSQ-UHFFFAOYSA-N 6-methoxy-5-propan-2-yloxy-2,3-dihydroinden-1-one Chemical compound C(C)(C)OC=1C=C2CCC(C2=CC=1OC)=O TWEJJOTUOVZLSQ-UHFFFAOYSA-N 0.000 description 1
• DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
• KYHQZNGJUGFTGR-LURJTMIESA-N 7-[(2s)-2-hydroxypropyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C[C@@H](O)C KYHQZNGJUGFTGR-LURJTMIESA-N 0.000 description 1
• FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical class C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
• 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
• 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
• 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
• 239000000775 AMPA receptor antagonist Substances 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 206010000117 Abnormal behaviour Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
• 108010013043 Acetylesterase Proteins 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 206010001014 Acute polyneuropathies Diseases 0.000 description 1
• 208000001395 Acute radiation syndrome Diseases 0.000 description 1
• 102000011690 Adiponectin Human genes 0.000 description 1
• 108010076365 Adiponectin Proteins 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
• 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• 208000003808 Amyloid Neuropathies Diseases 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 241000203069 Archaea Species 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
• MREBEPTUUMTTIA-PCLIKHOPSA-N Azimilide Chemical compound C1CN(C)CCN1CCCCN1C(=O)N(\N=C\C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O MREBEPTUUMTTIA-PCLIKHOPSA-N 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000012639 Balance disease Diseases 0.000 description 1
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BWSSMIJUDVUASQ-UHFFFAOYSA-N Benzylhydrochlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 BWSSMIJUDVUASQ-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 208000003508 Botulism Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 1
• 206010006797 Burns first degree Diseases 0.000 description 1
• 206010006802 Burns second degree Diseases 0.000 description 1
• 206010006803 Burns third degree Diseases 0.000 description 1
• 108010037003 Buserelin Proteins 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
• 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
• ICKGXCRLVAZABT-UHFFFAOYSA-N C=1C=C(C)C(F)=CC=1C(=O)N(CCCCC)CC1=NC2=CC=CC=C2N1CC1=CC=CC=C1C Chemical compound C=1C=C(C)C(F)=CC=1C(=O)N(CCCCC)CC1=NC2=CC=CC=C2N1CC1=CC=CC=C1C ICKGXCRLVAZABT-UHFFFAOYSA-N 0.000 description 1
• RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
• MEYPAYJYAZKERR-JLHYYAGUSA-N CGP 28014 Chemical compound CCCN(CCC)\C=N\C1=CC=CC(=O)N1 MEYPAYJYAZKERR-JLHYYAGUSA-N 0.000 description 1
• IQLBYADEGBUEDZ-UHFFFAOYSA-N COC1=C(C=CC=C1OCCN1CCCC1)C1=CC=CC(=N1)N Chemical compound COC1=C(C=CC=C1OCCN1CCCC1)C1=CC=CC(=N1)N IQLBYADEGBUEDZ-UHFFFAOYSA-N 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• QLTVVOATEHFXLT-UHFFFAOYSA-N Cadralazine Chemical compound CCOC(=O)NNC1=CC=C(N(CC)CC(C)O)N=N1 QLTVVOATEHFXLT-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 241000589875 Campylobacter jejuni Species 0.000 description 1
• 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 101000832687 Cavia porcellus 3-alpha-hydroxysteroid sulfotransferase Proteins 0.000 description 1
• 101000643834 Cavia porcellus 3-beta-hydroxysteroid sulfotransferase Proteins 0.000 description 1
• 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
• 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
• 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
• 206010008088 Cerebral artery embolism Diseases 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• 206010008132 Cerebral thrombosis Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
• 101710150887 Cholecystokinin A Proteins 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 241000588879 Chromobacterium violaceum Species 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• IPOBOOXFSRWSHL-UHFFFAOYSA-N Cibenzoline Chemical compound C=1C=CC=CC=1C1(C=2C=CC=CC=2)CC1C1=NCCN1 IPOBOOXFSRWSHL-UHFFFAOYSA-N 0.000 description 1
• BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
• 102100022641 Coagulation factor IX Human genes 0.000 description 1
• 102100023804 Coagulation factor VII Human genes 0.000 description 1
• ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 208000002330 Congenital Heart Defects Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010062346 Congenital neuropathy Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
• 206010011469 Crying Diseases 0.000 description 1
• 208000012514 Cumulative Trauma disease Diseases 0.000 description 1
• 102000005927 Cysteine Proteases Human genes 0.000 description 1
• 108010005843 Cysteine Proteases Proteins 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 208000027219 Deficiency disease Diseases 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012434 Dermatitis allergic Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 208000003164 Diplopia Diseases 0.000 description 1
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
• JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
• ZLVMAMIPILWYHQ-INIZCTEOSA-N Docarpamine Chemical compound CCOC(=O)OC1=CC=C(CCNC(=O)[C@H](CCSC)NC(C)=O)C=C1OC(=O)OCC ZLVMAMIPILWYHQ-INIZCTEOSA-N 0.000 description 1
• 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
• 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
• 102000015554 Dopamine receptor Human genes 0.000 description 1
• 108050004812 Dopamine receptor Proteins 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 208000030814 Eating disease Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010069808 Electrical burn Diseases 0.000 description 1
• 102000010180 Endothelin receptor Human genes 0.000 description 1
• 108050001739 Endothelin receptor Proteins 0.000 description 1
• 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
• LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 1
• 241000283087 Equus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 206010015226 Erythema nodosum Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 1
• 108010076282 Factor IX Proteins 0.000 description 1
• 108010014172 Factor V Proteins 0.000 description 1
• 108010023321 Factor VII Proteins 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 108010074864 Factor XI Proteins 0.000 description 1
• 108010080865 Factor XII Proteins 0.000 description 1
• 102000000429 Factor XII Human genes 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 241000282323 Felidae Species 0.000 description 1
• 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
• 108010029961 Filgrastim Proteins 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 229940121869 GABA A receptor agonist Drugs 0.000 description 1
• 102000004300 GABA-A Receptors Human genes 0.000 description 1
• 108090000839 GABA-A Receptors Proteins 0.000 description 1
• WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
• AQTITSBNGSVQNZ-UHFFFAOYSA-N GYKI 52895 Chemical compound N=1NC(C)CC2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 AQTITSBNGSVQNZ-UHFFFAOYSA-N 0.000 description 1
• 102400001370 Galanin Human genes 0.000 description 1
• 101800002068 Galanin Proteins 0.000 description 1
• XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
• 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
• FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
• 229940122459 Glutamate antagonist Drugs 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
• 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• ZHPLPRUARZZBET-UHFFFAOYSA-N Gossypetin Natural products O1C2=C(O)C(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 ZHPLPRUARZZBET-UHFFFAOYSA-N 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
• INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 101150021206 HST3 gene Proteins 0.000 description 1
• 101150077931 HST4 gene Proteins 0.000 description 1
• 208000024659 Hemostatic disease Diseases 0.000 description 1
• 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 1
• 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 description 1
• 229940127336 Hormone Receptor Agonists Drugs 0.000 description 1
• 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
• 241000598171 Human adenovirus sp. Species 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
• ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010021518 Impaired gastric emptying Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010021639 Incontinence Diseases 0.000 description 1
• 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
• 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
• 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
• 108010005716 Interferon beta-1a Proteins 0.000 description 1
• 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
• 229940127492 Kainate Receptor Antagonists Drugs 0.000 description 1
• 229940123572 Kainate receptor antagonist Drugs 0.000 description 1
• 206010023379 Ketoacidosis Diseases 0.000 description 1
• 208000007976 Ketosis Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 1
• JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 1
• 102100031775 Leptin receptor Human genes 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
• 229940127470 Lipase Inhibitors Drugs 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000010415 Low Vision Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 108010000410 MSH receptor Proteins 0.000 description 1
• 206010054805 Macroangiopathy Diseases 0.000 description 1
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
• 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
• 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
• 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
• 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
• 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
• 241001599018 Melanogaster Species 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
• 206010070909 Metabolic cardiomyopathy Diseases 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
• 208000034819 Mobility Limitation Diseases 0.000 description 1
• 206010027910 Mononeuritis Diseases 0.000 description 1
• 206010061296 Motor dysfunction Diseases 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101100477601 Mus musculus Sirt3 gene Proteins 0.000 description 1
• 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
• 241000186362 Mycobacterium leprae Species 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 1
• DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
• FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
• WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
• JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 1
• BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
• 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
• 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 1
• 102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 description 1
• 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029148 Nephrolithiasis Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 208000001738 Nervous System Trauma Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 101710138657 Neurotoxin Proteins 0.000 description 1
• YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
• 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
• OEBPANQZQGQPHF-UHFFFAOYSA-N Nifekalant Chemical compound O=C1N(C)C(=O)N(C)C(NCCN(CCO)CCCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 OEBPANQZQGQPHF-UHFFFAOYSA-N 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
• 108091093105 Nuclear DNA Proteins 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
• 108010016076 Octreotide Proteins 0.000 description 1
• 208000014723 Oculomotor Nerve disease Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 102000003840 Opioid Receptors Human genes 0.000 description 1
• 108090000137 Opioid Receptors Proteins 0.000 description 1
• 229940123730 Orexin receptor antagonist Drugs 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 241000283898 Ovis Species 0.000 description 1
• 208000007542 Paresis Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
• 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
• BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
• UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 208000005374 Poisoning Diseases 0.000 description 1
• 108091026813 Poly(ADPribose) Proteins 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 229940127315 Potassium Channel Openers Drugs 0.000 description 1
• IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000024777 Prion disease Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101800004937 Protein C Proteins 0.000 description 1
• 102000017975 Protein C Human genes 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 206010068142 Radiation sickness syndrome Diseases 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 101000599815 Rattus norvegicus Probable E3 ubiquitin-protein ligase IRF2BPL Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
• QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
• 102000007156 Resistin Human genes 0.000 description 1
• 108010047909 Resistin Proteins 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 208000021811 Sandhoff disease Diseases 0.000 description 1
• 101800001700 Saposin-D Proteins 0.000 description 1
• 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
• 208000013140 Sensorimotor disease Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
• 229940078753 Sirtuin inhibitor Drugs 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010040799 Skin atrophy Diseases 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 229940127505 Sodium Channel Antagonists Drugs 0.000 description 1
• 108010052164 Sodium Channels Proteins 0.000 description 1
• 102000018674 Sodium Channels Human genes 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 1
• 101710145796 Staphylokinase Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 239000004376 Sucralose Substances 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 206010053615 Thermal burn Diseases 0.000 description 1
• 229940123464 Thiazolidinedione Drugs 0.000 description 1
• GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
• 229940122388 Thrombin inhibitor Drugs 0.000 description 1
• 102000003938 Thromboxane Receptors Human genes 0.000 description 1
• 108090000300 Thromboxane Receptors Proteins 0.000 description 1
• 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
• 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
• NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 description 1
• UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
• GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• 102000005630 Urocortins Human genes 0.000 description 1
• 108010059705 Urocortins Proteins 0.000 description 1
• 208000005181 Varicella Zoster Virus Infection Diseases 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 206010053649 Vascular rupture Diseases 0.000 description 1
• 206010047163 Vasospasm Diseases 0.000 description 1
• DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
• 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
• ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
• 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
• BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
• IJOUKWCBVUMMCR-YDKGJHSESA-N [(3R,4S,5R)-5-[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl] acetate Chemical compound CC(=O)OC1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O IJOUKWCBVUMMCR-YDKGJHSESA-N 0.000 description 1
• YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
• 229960000446 abciximab Drugs 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000012084 abdominal surgery Methods 0.000 description 1
• 229960002632 acarbose Drugs 0.000 description 1
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
• 229960000571 acetazolamide Drugs 0.000 description 1
• 229960000583 acetic acid Drugs 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 208000009621 actinic keratosis Diseases 0.000 description 1
• 230000036982 action potential Effects 0.000 description 1
• 201000001509 acute urate nephropathy Diseases 0.000 description 1
• 239000002467 adenosine A2a receptor antagonist Substances 0.000 description 1
• 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 239000000808 adrenergic beta-agonist Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 229950007884 alacepril Drugs 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 239000003288 aldose reductase inhibitor Substances 0.000 description 1
• 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 239000002160 alpha blocker Substances 0.000 description 1
• 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
• 229960002213 alprenolol Drugs 0.000 description 1
• PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
• 229960000711 alprostadil Drugs 0.000 description 1
• 229960003318 alteplase Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
• 229960002576 amiloride Drugs 0.000 description 1
• 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• 229960003556 aminophylline Drugs 0.000 description 1
• PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 229960002105 amrinone Drugs 0.000 description 1
• RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
• 229960003116 amyl nitrite Drugs 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
• LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000002095 anti-migrative effect Effects 0.000 description 1
• 230000002927 anti-mitotic effect Effects 0.000 description 1
• 230000002555 anti-neurodegenerative effect Effects 0.000 description 1
• 230000000842 anti-protozoal effect Effects 0.000 description 1
• 230000001262 anti-secretory effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940127090 anticoagulant agent Drugs 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 229940127088 antihypertensive drug Drugs 0.000 description 1
• 239000003524 antilipemic agent Substances 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
• 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
• 229940125710 antiobesity agent Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 230000009925 apoptotic mechanism Effects 0.000 description 1
• 239000002830 appetite depressant Substances 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• NZLBHDRPUJLHCE-UHFFFAOYSA-N aprindine Chemical compound C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 NZLBHDRPUJLHCE-UHFFFAOYSA-N 0.000 description 1
• 229960004957 aprindine Drugs 0.000 description 1
• KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
• 229960003856 argatroban Drugs 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229940003504 avonex Drugs 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229950001786 azimilide Drugs 0.000 description 1
• IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
• 229960004988 azosemide Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000033590 base-excision repair Effects 0.000 description 1
• 229960002210 batroxobin Drugs 0.000 description 1
• 229960004530 benazepril Drugs 0.000 description 1
• 238000005452 bending Methods 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
• 229960000911 benserazide Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
• 229960001541 benzthiazide Drugs 0.000 description 1
• 229950007003 benzylhydrochlorothiazide Drugs 0.000 description 1
• 229960002890 beraprost Drugs 0.000 description 1
• YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
• 229960003588 bevantolol Drugs 0.000 description 1
• HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 1
• IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
• 229960000516 bezafibrate Drugs 0.000 description 1
• 239000007998 bicine buffer Substances 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 238000005842 biochemical reaction Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 230000007698 birth defect Effects 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 239000003114 blood coagulation factor Substances 0.000 description 1
• 229960000182 blood factors Drugs 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 208000015322 bone marrow disease Diseases 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 229960001467 bortezomib Drugs 0.000 description 1
• 229960003065 bosentan Drugs 0.000 description 1
• SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical compound O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 description 1
• 210000003461 brachial plexus Anatomy 0.000 description 1
• 201000006431 brachial plexus neuropathy Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 229960002624 bretylium tosilate Drugs 0.000 description 1
• KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 1
• DQGFCLJXYFXXIJ-LFIBNONCSA-N budralazine Chemical compound C1=CC=C2C(N/N=C(C)/C=C(C)C)=NN=CC2=C1 DQGFCLJXYFXXIJ-LFIBNONCSA-N 0.000 description 1
• 229950001730 budralazine Drugs 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 229960002467 bunazosin Drugs 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
• CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
• 229960002719 buserelin Drugs 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 229960005211 cadralazine Drugs 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229960005069 calcium Drugs 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
• 229960000932 candesartan Drugs 0.000 description 1
• 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
• QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
• 229960004205 carbidopa Drugs 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 229940097217 cardiac glycoside Drugs 0.000 description 1
• 239000002368 cardiac glycoside Substances 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 238000007675 cardiac surgery Methods 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
• 229950008486 carperitide Drugs 0.000 description 1
• 150000003943 catecholamines Chemical class 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 230000010094 cellular senescence Effects 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 150000001793 charged compounds Chemical class 0.000 description 1
• MTCMTKNMZCPKLX-UHFFFAOYSA-N chembl359570 Chemical compound N=1OC=2C=C3NC(=O)CC3=CC=2C=1CCC(CC1)CCN1CC1=CC=CC=C1 MTCMTKNMZCPKLX-UHFFFAOYSA-N 0.000 description 1
• UXJFDYIHRJGPFS-WPWMEQJKSA-N chembl380797 Chemical compound C=1C=CC=C(\N=C\C=2C3=CC=CC=C3C=CC=2O)C=1C(=O)NC(C)C1=CC=CC=C1 UXJFDYIHRJGPFS-WPWMEQJKSA-N 0.000 description 1
• PPMPPMKWHZDSNI-UHFFFAOYSA-N chembl92463 Chemical compound N=1OC2=CC(O)=CC=C2C=1CCC(CC1)CCN1CC1=CC=CC=C1 PPMPPMKWHZDSNI-UHFFFAOYSA-N 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 229960004757 cibenzoline Drugs 0.000 description 1
• GQSGZTBDVNUIQS-DGCLKSJQSA-N ciclonicate Chemical compound C1C(C)(C)C[C@H](C)C[C@H]1OC(=O)C1=CC=CN=C1 GQSGZTBDVNUIQS-DGCLKSJQSA-N 0.000 description 1
• 229960003025 ciclonicate Drugs 0.000 description 1
• 229960005025 cilazapril Drugs 0.000 description 1
• JQRZBPFGBRIWSN-YOTVLOEGSA-N cilazapril monohydrate Chemical compound O.C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 JQRZBPFGBRIWSN-YOTVLOEGSA-N 0.000 description 1
• 230000001886 ciliary effect Effects 0.000 description 1
• 229960004588 cilostazol Drugs 0.000 description 1
• RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
• 229960001653 citalopram Drugs 0.000 description 1
• 229960001284 citicoline Drugs 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 229950003072 clinofibrate Drugs 0.000 description 1
• 229960002286 clodronic acid Drugs 0.000 description 1
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
• 229960001214 clofibrate Drugs 0.000 description 1
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
• 229960004414 clomethiazole Drugs 0.000 description 1
• 229960004893 cloranolol Drugs 0.000 description 1
• XYCMOTOFHFTUIU-UHFFFAOYSA-N cloranolol Chemical compound CC(C)(C)NCC(O)COC1=CC(Cl)=CC=C1Cl XYCMOTOFHFTUIU-UHFFFAOYSA-N 0.000 description 1
• 239000011436 cob Substances 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 235000017471 coenzyme Q10 Nutrition 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
• 229950005210 colforsin Drugs 0.000 description 1
• 238000009096 combination chemotherapy Methods 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 238000011254 conventional chemotherapy Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 210000003792 cranial nerve Anatomy 0.000 description 1
• 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 210000000695 crystalline len Anatomy 0.000 description 1
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• MKNXBRLZBFVUPV-UHFFFAOYSA-L cyclopenta-1,3-diene;dichlorotitanium Chemical compound Cl[Ti]Cl.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 MKNXBRLZBFVUPV-UHFFFAOYSA-L 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960004969 dalteparin Drugs 0.000 description 1
• 229940018872 dalteparin sodium Drugs 0.000 description 1
• 229960004776 danaparoid sodium Drugs 0.000 description 1
• RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical compound CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 description 1
• 229960002947 dapiprazole Drugs 0.000 description 1
• OBATZBGFDSVCJD-UHFFFAOYSA-N de-O-acetyl-lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(O)C1OC1OC(CO)C(O)C(O)C1O OBATZBGFDSVCJD-UHFFFAOYSA-N 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
• VHSBBVZJABQOSG-MRXNPFEDSA-N denopamine Chemical compound C1=C(OC)C(OC)=CC=C1CCNC[C@@H](O)C1=CC=C(O)C=C1 VHSBBVZJABQOSG-MRXNPFEDSA-N 0.000 description 1
• 229950007304 denopamine Drugs 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 229940063223 depo-provera Drugs 0.000 description 1
• 229960003914 desipramine Drugs 0.000 description 1
• OBATZBGFDSVCJD-LALPQLPRSA-N deslanoside Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OBATZBGFDSVCJD-LALPQLPRSA-N 0.000 description 1
• 229960001324 deslanoside Drugs 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960004597 dexfenfluramine Drugs 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002059 diagnostic imaging Methods 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• 229960004042 diazoxide Drugs 0.000 description 1
• NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
• 229960003839 dienestrol Drugs 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• 229940064790 dilantin Drugs 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
• DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960001089 dobutamine Drugs 0.000 description 1
• 229950006045 docarpamine Drugs 0.000 description 1
• IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
• 229960002994 dofetilide Drugs 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
• 230000028436 dopamine uptake Effects 0.000 description 1
• 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
• 229940005501 dopaminergic agent Drugs 0.000 description 1
• RYBJORHCUPVNMB-UHFFFAOYSA-N dopexamine Chemical compound C1=C(O)C(O)=CC=C1CCNCCCCCCNCCC1=CC=CC=C1 RYBJORHCUPVNMB-UHFFFAOYSA-N 0.000 description 1
• 229960001857 dopexamine Drugs 0.000 description 1
• 208000029444 double vision Diseases 0.000 description 1
• 229960001389 doxazosin Drugs 0.000 description 1
• RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
• ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 description 1
• 229960002084 dronedarone Drugs 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 235000005686 eating Nutrition 0.000 description 1
• QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
• 229950009041 edaravone Drugs 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 230000004970 emotional disturbance Effects 0.000 description 1
• PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 description 1
• 229960001142 encainide Drugs 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 229960002179 ephedrine Drugs 0.000 description 1
• VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• 229930013356 epothilone Natural products 0.000 description 1
• HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
• 229960004563 eprosartan Drugs 0.000 description 1
• OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
• RHGUXDUPXYFCTE-ZWNOBZJWSA-N ergoline Chemical class C1=CC([C@@H]2[C@H](NCCC2)C2)=C3C2=CNC3=C1 RHGUXDUPXYFCTE-ZWNOBZJWSA-N 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
• 229960003199 etacrynic acid Drugs 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 230000005496 eutectics Effects 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 208000004526 exfoliative dermatitis Diseases 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 230000006624 extrinsic pathway Effects 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 229960004222 factor ix Drugs 0.000 description 1
• 229940012413 factor vii Drugs 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 150000002190 fatty acyls Chemical group 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 229960001582 fenfluramine Drugs 0.000 description 1
• 229950004395 fengabine Drugs 0.000 description 1
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• 229960004177 filgrastim Drugs 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 235000011990 fisetin Nutrition 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
• 229960002011 fludrocortisone Drugs 0.000 description 1
• RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
• 229960003028 flumethiazide Drugs 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• 229960003667 flupirtine Drugs 0.000 description 1
• SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
• 229960003528 flurazepam Drugs 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960000868 fluvastatin sodium Drugs 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• 230000002431 foraging effect Effects 0.000 description 1
• 229960002490 fosinopril Drugs 0.000 description 1
• 150000002243 furanoses Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• 229950004346 gaboxadol Drugs 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 229940074391 gallic acid Drugs 0.000 description 1
• 235000004515 gallic acid Nutrition 0.000 description 1
• 229960000457 gallopamil Drugs 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• 229950006567 ganaxolone Drugs 0.000 description 1
• GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 229960004580 glibenclamide Drugs 0.000 description 1
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
• 229960001381 glipizide Drugs 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
• 150000002303 glucose derivatives Chemical class 0.000 description 1
• 230000007967 glucose restriction Effects 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
• YRRAGUMVDQQZIY-UHFFFAOYSA-N gossypetin Chemical compound C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C(O)=C2O1 YRRAGUMVDQQZIY-UHFFFAOYSA-N 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229960004553 guanabenz Drugs 0.000 description 1
• 229960002048 guanfacine Drugs 0.000 description 1
• IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
• 229960002706 gusperimus Drugs 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000008821 health effect Effects 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000002439 hemostatic effect Effects 0.000 description 1
• ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
• 229940095529 heparin calcium Drugs 0.000 description 1
• 229960001008 heparin sodium Drugs 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000006195 histone acetylation Effects 0.000 description 1
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
• 231100000652 hormesis Toxicity 0.000 description 1
• 239000003668 hormone analog Substances 0.000 description 1
• 239000003667 hormone antagonist Substances 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 102000056614 human NPPA Human genes 0.000 description 1
• 244000052637 human pathogen Species 0.000 description 1
• 229940034998 human von willebrand factor Drugs 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
• 229960003313 hydroflumethiazide Drugs 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 208000010522 hyperproinsulinemia Diseases 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 229960002491 ibudilast Drugs 0.000 description 1
• 229960004053 ibutilide Drugs 0.000 description 1
• 229960002600 icosapent ethyl Drugs 0.000 description 1
• 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
• 229960003998 ifenprodil Drugs 0.000 description 1
• BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 description 1
• 229950004274 ifetroban Drugs 0.000 description 1
• 229960002240 iloprost Drugs 0.000 description 1
• HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 229960001195 imidapril Drugs 0.000 description 1
• KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 125000005945 imidazopyridyl group Chemical group 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 229940124589 immunosuppressive drug Drugs 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 229960003422 indobufen Drugs 0.000 description 1
• AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 238000009413 insulation Methods 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000003871 intestinal function Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 201000010849 intracranial embolism Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000006623 intrinsic pathway Effects 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000001875 irritant dermatitis Diseases 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 208000023589 ischemic disease Diseases 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 229960003350 isoniazid Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
• 239000002873 kainic acid receptor antagonist Substances 0.000 description 1
• 230000003780 keratinization Effects 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229960004340 lacidipine Drugs 0.000 description 1
• GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960002614 lanatoside c Drugs 0.000 description 1
• 229950005862 lazabemide Drugs 0.000 description 1
• 108010019813 leptin receptors Proteins 0.000 description 1
• 229960004294 lercanidipine Drugs 0.000 description 1
• ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 229960001614 levamisole Drugs 0.000 description 1
• IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
• 229960000831 levobunolol Drugs 0.000 description 1
• WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 1
• 229960000692 levosimendan Drugs 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000004132 lipogenesis Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229960003587 lisuride Drugs 0.000 description 1
• XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
• 229910052808 lithium carbonate Inorganic materials 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000002171 loop diuretic Substances 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 229940127215 low-molecular weight heparin Drugs 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 229940124302 mTOR inhibitor Drugs 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 229910001425 magnesium ion Inorganic materials 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004616 medroxyprogesterone Drugs 0.000 description 1
• 229950004994 meglitinide Drugs 0.000 description 1
• ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
• 230000036630 mental development Effects 0.000 description 1
• 229960004635 mesna Drugs 0.000 description 1
• 230000006371 metabolic abnormality Effects 0.000 description 1
• 125000005341 metaphosphate group Chemical group 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
• 229960003746 metildigoxin Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 229960003574 milrinone Drugs 0.000 description 1
• PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 229960001785 mirtazapine Drugs 0.000 description 1
• RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 230000004065 mitochondrial dysfunction Effects 0.000 description 1
• 229950000844 mizoribine Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 229950010854 mofegiline Drugs 0.000 description 1
• SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
• 229940126403 monoamine reuptake inhibitor Drugs 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 208000013734 mononeuritis simplex Diseases 0.000 description 1
• 150000002772 monosaccharides Chemical group 0.000 description 1
• 108010075698 monteplase Proteins 0.000 description 1
• 229950005805 monteplase Drugs 0.000 description 1
• LFTFGCDECFPSQD-UHFFFAOYSA-N moprolol Chemical compound COC1=CC=CC=C1OCC(O)CNC(C)C LFTFGCDECFPSQD-UHFFFAOYSA-N 0.000 description 1
• 229950002481 moprolol Drugs 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 208000022084 motor paralysis Diseases 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 230000004220 muscle function Effects 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• 235000007743 myricetin Nutrition 0.000 description 1
• 229940116852 myricetin Drugs 0.000 description 1
• YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 1
• JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 1
• FABUFRPUJYOJDP-UHFFFAOYSA-N n-[2-[3-(1-benzylpiperidin-4-yl)propanoyl]-1h-indol-5-yl]acetamide Chemical compound C=1C2=CC(NC(=O)C)=CC=C2NC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 FABUFRPUJYOJDP-UHFFFAOYSA-N 0.000 description 1
• OEDAMXCGASJANJ-UHFFFAOYSA-N n-[3-[2-(1-benzylpiperidin-4-yl)ethyl]-1,2-benzoxazol-6-yl]acetamide Chemical compound N=1OC2=CC(NC(=O)C)=CC=C2C=1CCC(CC1)CCN1CC1=CC=CC=C1 OEDAMXCGASJANJ-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• DWMQCWYIMZWFPL-UHFFFAOYSA-N n-methyl-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine;hydrochloride Chemical compound Cl.C1=CC=C2C(N(CC#C)C)CCC2=C1 DWMQCWYIMZWFPL-UHFFFAOYSA-N 0.000 description 1
• CJRQAPHWCGEATR-UHFFFAOYSA-N n-methyl-n-prop-2-ynylbutan-2-amine Chemical compound CCC(C)N(C)CC#C CJRQAPHWCGEATR-UHFFFAOYSA-N 0.000 description 1
• BSNWMBHBPLPDNI-UHFFFAOYSA-N n-methyl-n-prop-2-ynylpentan-2-amine Chemical compound CCCC(C)N(C)CC#C BSNWMBHBPLPDNI-UHFFFAOYSA-N 0.000 description 1
• CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000003887 narcotic antagonist Substances 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
• 229960000698 nateglinide Drugs 0.000 description 1
• 229950002774 nateplase Drugs 0.000 description 1
• 230000001452 natriuretic effect Effects 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• JCSREICEMHWFAY-HUUCEWRRSA-N naxagolide Chemical compound C1=C(O)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 JCSREICEMHWFAY-HUUCEWRRSA-N 0.000 description 1
• 229950005651 naxagolide Drugs 0.000 description 1
• 229960000619 nebivolol Drugs 0.000 description 1
• 201000009925 nephrosclerosis Diseases 0.000 description 1
• 208000019382 nerve compression syndrome Diseases 0.000 description 1
• 208000028412 nervous system injury Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 208000029974 neurofibrosarcoma Diseases 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 210000000715 neuromuscular junction Anatomy 0.000 description 1
• 230000007426 neuronal cell dysfunction Effects 0.000 description 1
• 230000006764 neuronal dysfunction Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 239000002581 neurotoxin Substances 0.000 description 1
• 231100000618 neurotoxin Toxicity 0.000 description 1
• 239000003900 neurotrophic factor Substances 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229960003642 nicergoline Drugs 0.000 description 1
• QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229950008576 nifekalant Drugs 0.000 description 1
• KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
• 229960001454 nitrazepam Drugs 0.000 description 1
• 230000000422 nocturnal effect Effects 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 229960001158 nortriptyline Drugs 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• PXMPJJIXWLEXEH-UHFFFAOYSA-N oct-2-ynedioic acid Chemical compound OC(=O)CCCCC#CC(O)=O PXMPJJIXWLEXEH-UHFFFAOYSA-N 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 229960002700 octreotide Drugs 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000003565 oculomotor Effects 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 description 1
• 229950005421 olprinone Drugs 0.000 description 1
• FDQZTPPHJRQRQQ-NZPQQUJLSA-N omega-conotoxin GVIA Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N4C[C@H](O)C[C@H]4C(=O)N1)=O)CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N2)=O)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 FDQZTPPHJRQRQQ-NZPQQUJLSA-N 0.000 description 1
• 229940127234 oral contraceptive Drugs 0.000 description 1
• 239000003539 oral contraceptive agent Substances 0.000 description 1
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
• 229960001243 orlistat Drugs 0.000 description 1
• 239000002337 osmotic diuretic agent Substances 0.000 description 1
• 229940097271 other diuretics in atc Drugs 0.000 description 1
• 229940094984 other estrogen in atc Drugs 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
• 208000021090 palsy Diseases 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229960001789 papaverine Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
• 229960002035 penbutolol Drugs 0.000 description 1
• 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
• 229950008492 pentopril Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• 229960001476 pentoxifylline Drugs 0.000 description 1
• 230000008447 perception Effects 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 229960004851 pergolide Drugs 0.000 description 1
• YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
• CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 description 1
• 229960000989 perhexiline Drugs 0.000 description 1
• 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229960003562 phentermine Drugs 0.000 description 1
• 229960001999 phentolamine Drugs 0.000 description 1
• MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
• 229960000395 phenylpropanolamine Drugs 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• BCQTVJKBTWGHCX-UHFFFAOYSA-N pilsicainide Chemical compound CC1=CC=CC(C)=C1NC(=O)CC1(CCC2)N2CCC1 BCQTVJKBTWGHCX-UHFFFAOYSA-N 0.000 description 1
• 229950010769 pilsicainide Drugs 0.000 description 1
• 229960002164 pimobendan Drugs 0.000 description 1
• GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
• 229960002310 pinacidil Drugs 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 229960001085 piretanide Drugs 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 208000006473 polyradiculopathy Diseases 0.000 description 1
• 229960005483 polythiazide Drugs 0.000 description 1
• 229920000046 polythiazide Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229960003975 potassium Drugs 0.000 description 1
• JTZQCHFUGHIPDF-RYVBEKKQSA-M potassium canrenoate Chemical compound [K+].O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 JTZQCHFUGHIPDF-RYVBEKKQSA-M 0.000 description 1
• 229960000206 potassium canrenoate Drugs 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 239000003450 potassium channel blocker Substances 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229960003089 pramipexole Drugs 0.000 description 1
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
• 229960002847 prasterone Drugs 0.000 description 1
• VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
• 229960001495 pravastatin sodium Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229960001989 prenylamine Drugs 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 210000002250 primary motor neuron Anatomy 0.000 description 1
• NYWSLZMTZNODJM-SDUQVVOESA-N primycin Natural products CCCC[C@H]1[C@H](O)[C@H](C)CC[C@@H](O)CCC[C@@H](O)CCC[C@@H](O)C(=C[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@H](O)CCCCC(=C[C@@H](C)[C@@H](OC1=O)[C@H](C)[C@H](O)CCCNC(=N)N)C)C NYWSLZMTZNODJM-SDUQVVOESA-N 0.000 description 1
• 229950010664 primycin Drugs 0.000 description 1
• 239000003805 procoagulant Substances 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 150000003146 progesterones Chemical class 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 150000003815 prostacyclins Chemical class 0.000 description 1
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 229940076372 protein antagonist Drugs 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 229960004767 proxyphylline Drugs 0.000 description 1
• KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
• 229960003908 pseudoephedrine Drugs 0.000 description 1
• 229940121374 purinergic receptor antagonist Drugs 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• PMXCMJLOPOFPBT-HNNXBMFYSA-N purvalanol A Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PMXCMJLOPOFPBT-HNNXBMFYSA-N 0.000 description 1
• 150000003214 pyranose derivatives Chemical group 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 1
• 229950001037 quinpirole Drugs 0.000 description 1
• WYJAPUKIYAZSEM-UHFFFAOYSA-N rac-Eburnamonin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(=O)N5C2=C1 WYJAPUKIYAZSEM-UHFFFAOYSA-N 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 239000000941 radioactive substance Substances 0.000 description 1
• 229960004432 raltitrexed Drugs 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• 229940045847 receptor mimetic Drugs 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000034986 regulation of gene silencing Effects 0.000 description 1
• 210000002254 renal artery Anatomy 0.000 description 1
• 229960002354 repaglinide Drugs 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000002336 repolarization Effects 0.000 description 1
• BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
• 229960003147 reserpine Drugs 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 108020004418 ribosomal RNA Proteins 0.000 description 1
• 229960004181 riluzole Drugs 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
• 229960001879 ropinirole Drugs 0.000 description 1
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
• MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 210000003079 salivary gland Anatomy 0.000 description 1
• FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 description 1
• 229950005789 sarpogrelate Drugs 0.000 description 1
• 108010073863 saruplase Proteins 0.000 description 1
• 230000036186 satiety Effects 0.000 description 1
• 235000019627 satiety Nutrition 0.000 description 1
• 239000003229 sclerosing agent Substances 0.000 description 1
• 208000008864 scrapie Diseases 0.000 description 1
• 229940116351 sebacate Drugs 0.000 description 1
• CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
• 208000008742 seborrheic dermatitis Diseases 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229930000044 secondary metabolite Natural products 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
• 229960003946 selegiline Drugs 0.000 description 1
• 230000037307 sensitive skin Effects 0.000 description 1
• 230000037152 sensory function Effects 0.000 description 1
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 229960002073 sertraline Drugs 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
• 229960004425 sibutramine Drugs 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229960004058 simfibrate Drugs 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 230000005783 single-strand break Effects 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 230000005586 smoking cessation Effects 0.000 description 1
• 229940083542 sodium Drugs 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000003195 sodium channel blocking agent Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229960001790 sodium citrate Drugs 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 210000001032 spinal nerve Anatomy 0.000 description 1
• 229960002909 spirapril Drugs 0.000 description 1
• HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
• 108700035424 spirapril Proteins 0.000 description 1
• LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
• 229960002256 spironolactone Drugs 0.000 description 1
• ISFPDBUKMJDAJH-UHFFFAOYSA-N splitomicin Chemical compound C1=CC2=CC=CC=C2C2=C1OC(=O)CC2 ISFPDBUKMJDAJH-UHFFFAOYSA-N 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 229930002534 steroid glycoside Natural products 0.000 description 1
• 150000008143 steroidal glycosides Chemical class 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
• 235000019408 sucralose Nutrition 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 239000011593 sulfur Chemical group 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 229940127230 sympathomimetic drug Drugs 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229960002613 tamsulosin Drugs 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
• 229960002926 tedisamil Drugs 0.000 description 1
• CTIRHWCPXYGDGF-HDICACEKSA-N tedisamil Chemical compound [H][C@]12CN(CC3CC3)C[C@]([H])(CN(CC3CC3)C1)C21CCCC1 CTIRHWCPXYGDGF-HDICACEKSA-N 0.000 description 1
• 108091035539 telomere Proteins 0.000 description 1
• 210000003411 telomere Anatomy 0.000 description 1
• 102000055501 telomere Human genes 0.000 description 1
• 229960004084 temocapril Drugs 0.000 description 1
• FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 229960004558 terguride Drugs 0.000 description 1
• 229960005383 terodiline Drugs 0.000 description 1
• UISARWKNNNHPGI-UHFFFAOYSA-N terodiline Chemical compound C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 UISARWKNNNHPGI-UHFFFAOYSA-N 0.000 description 1
• RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 150000004685 tetrahydrates Chemical class 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 239000003868 thrombin inhibitor Substances 0.000 description 1
• 201000005665 thrombophilia Diseases 0.000 description 1
• MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
• 229960002961 ticlopidine hydrochloride Drugs 0.000 description 1
• 229960005013 tiotixene Drugs 0.000 description 1
• 229950001089 todralazine Drugs 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 210000000515 tooth Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229960005461 torasemide Drugs 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 108010060597 trapoxin A Proteins 0.000 description 1
• GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 description 1
• LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
• 229960004813 trichlormethiazide Drugs 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 1
• 229960002906 trimazosin Drugs 0.000 description 1
• 229960001177 trimetazidine Drugs 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 229940079023 tysabri Drugs 0.000 description 1
• 229960004747 ubidecarenone Drugs 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 229960001130 urapidil Drugs 0.000 description 1
• 208000019808 uric acid nephrolithiasis Diseases 0.000 description 1
• 239000000777 urocortin Substances 0.000 description 1
• NAUWTFJOPJWYOT-UHFFFAOYSA-N vanoxerine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(CCCC=2C=CC=CC=2)CC1 NAUWTFJOPJWYOT-UHFFFAOYSA-N 0.000 description 1
• 208000010531 varicella zoster infection Diseases 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 208000012908 vascular hemostatic disease Diseases 0.000 description 1
• 238000007631 vascular surgery Methods 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229960002726 vincamine Drugs 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 229960000744 vinpocetine Drugs 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000004260 weight control Methods 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1
• RKUQLAPSGZJLGP-UHFFFAOYSA-N xibenolol Chemical compound CC1=CC=CC(OCC(O)CNC(C)(C)C)=C1C RKUQLAPSGZJLGP-UHFFFAOYSA-N 0.000 description 1
• 229950001124 xibenolol Drugs 0.000 description 1
• 229940071104 xylenesulfonate Drugs 0.000 description 1
• BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
• 229960000317 yohimbine Drugs 0.000 description 1
• AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
• 229960002555 zidovudine Drugs 0.000 description 1
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
• 229960002769 zofenopril Drugs 0.000 description 1
• IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
• 108091058553 ω-conotoxin GVIA Proteins 0.000 description 1